WO2023273626A1 - Composition for treating alzheimer's disease and preparation method therefor - Google Patents
Composition for treating alzheimer's disease and preparation method therefor Download PDFInfo
- Publication number
- WO2023273626A1 WO2023273626A1 PCT/CN2022/092323 CN2022092323W WO2023273626A1 WO 2023273626 A1 WO2023273626 A1 WO 2023273626A1 CN 2022092323 W CN2022092323 W CN 2022092323W WO 2023273626 A1 WO2023273626 A1 WO 2023273626A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- parts
- group
- composition
- acanthopanax
- cistanche
- Prior art date
Links
- 208000024827 Alzheimer disease Diseases 0.000 title claims abstract description 27
- 239000000203 mixture Substances 0.000 title claims description 39
- 238000002360 preparation method Methods 0.000 title claims description 18
- 239000003814 drug Substances 0.000 claims abstract description 127
- 229940079593 drug Drugs 0.000 claims abstract description 115
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 54
- 241000336291 Cistanche deserticola Species 0.000 claims abstract description 17
- 230000006870 function Effects 0.000 claims abstract description 16
- 241000382455 Angelica sinensis Species 0.000 claims abstract description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 68
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 67
- 230000002829 reductive effect Effects 0.000 claims description 48
- 239000000843 powder Substances 0.000 claims description 42
- 241000125175 Angelica Species 0.000 claims description 27
- 235000001287 Guettarda speciosa Nutrition 0.000 claims description 27
- 239000000284 extract Substances 0.000 claims description 25
- 239000012153 distilled water Substances 0.000 claims description 21
- 241000005787 Cistanche Species 0.000 claims description 19
- 206010039966 Senile dementia Diseases 0.000 claims description 17
- 239000002674 ointment Substances 0.000 claims description 17
- 239000003826 tablet Substances 0.000 claims description 17
- 239000000341 volatile oil Substances 0.000 claims description 16
- 230000006378 damage Effects 0.000 claims description 15
- 239000002994 raw material Substances 0.000 claims description 13
- 206010027175 memory impairment Diseases 0.000 claims description 12
- 238000012545 processing Methods 0.000 claims description 12
- 241001632410 Eleutherococcus senticosus Species 0.000 claims description 10
- 239000002775 capsule Substances 0.000 claims description 10
- 239000012141 concentrate Substances 0.000 claims description 10
- 239000006071 cream Substances 0.000 claims description 10
- 239000000463 material Substances 0.000 claims description 10
- 230000001713 cholinergic effect Effects 0.000 claims description 9
- 230000006907 apoptotic process Effects 0.000 claims description 8
- 239000000706 filtrate Substances 0.000 claims description 8
- 230000036542 oxidative stress Effects 0.000 claims description 8
- 238000010992 reflux Methods 0.000 claims description 8
- 238000005303 weighing Methods 0.000 claims description 8
- 230000028709 inflammatory response Effects 0.000 claims description 7
- 210000002569 neuron Anatomy 0.000 claims description 7
- 239000008434 yi-zhi Substances 0.000 claims description 7
- 238000000605 extraction Methods 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 239000006187 pill Substances 0.000 claims description 5
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 abstract description 34
- 230000003014 reinforcing effect Effects 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 description 96
- 238000012360 testing method Methods 0.000 description 72
- 241000699670 Mus sp. Species 0.000 description 60
- 230000000694 effects Effects 0.000 description 53
- 241000700159 Rattus Species 0.000 description 40
- 238000000034 method Methods 0.000 description 38
- 210000004369 blood Anatomy 0.000 description 35
- 239000008280 blood Substances 0.000 description 35
- 239000000686 essence Substances 0.000 description 35
- 230000037396 body weight Effects 0.000 description 26
- 210000001320 hippocampus Anatomy 0.000 description 26
- 230000009191 jumping Effects 0.000 description 25
- 238000002474 experimental method Methods 0.000 description 22
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 21
- 230000014509 gene expression Effects 0.000 description 20
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 20
- 210000004556 brain Anatomy 0.000 description 19
- 230000007087 memory ability Effects 0.000 description 18
- 241000699666 Mus <mouse, genus> Species 0.000 description 17
- ZRJBHWIHUMBLCN-YQEJDHNASA-N huperzine A Chemical group N1C(=O)C=CC2=C1C[C@H]1\C(=C/C)[C@]2(N)CC(C)=C1 ZRJBHWIHUMBLCN-YQEJDHNASA-N 0.000 description 17
- 238000012549 training Methods 0.000 description 17
- 230000006872 improvement Effects 0.000 description 16
- 239000000047 product Substances 0.000 description 16
- 230000007812 deficiency Effects 0.000 description 15
- 238000010171 animal model Methods 0.000 description 14
- 208000035475 disorder Diseases 0.000 description 14
- 208000000044 Amnesia Diseases 0.000 description 13
- 230000006735 deficit Effects 0.000 description 13
- 230000005056 memory consolidation Effects 0.000 description 13
- 238000011160 research Methods 0.000 description 13
- 239000002547 new drug Substances 0.000 description 12
- 230000008506 pathogenesis Effects 0.000 description 12
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 11
- 102100033639 Acetylcholinesterase Human genes 0.000 description 11
- ZRJBHWIHUMBLCN-SEQYCRGISA-N Huperzine A Natural products N1C(=O)C=CC2=C1C[C@H]1/C(=C/C)[C@]2(N)CC(C)=C1 ZRJBHWIHUMBLCN-SEQYCRGISA-N 0.000 description 11
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 11
- 206010062717 Increased upper airway secretion Diseases 0.000 description 11
- 208000026139 Memory disease Diseases 0.000 description 11
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 11
- ZRJBHWIHUMBLCN-UHFFFAOYSA-N Shuangyiping Natural products N1C(=O)C=CC2=C1CC1C(=CC)C2(N)CC(C)=C1 ZRJBHWIHUMBLCN-UHFFFAOYSA-N 0.000 description 11
- 108010064539 amyloid beta-protein (1-42) Proteins 0.000 description 11
- 230000006984 memory degeneration Effects 0.000 description 11
- 208000023060 memory loss Diseases 0.000 description 11
- 208000026435 phlegm Diseases 0.000 description 11
- ZRJBHWIHUMBLCN-BMIGLBTASA-N rac-huperzine A Natural products N1C(=O)C=CC2=C1C[C@@H]1C(=CC)[C@@]2(N)CC(C)=C1 ZRJBHWIHUMBLCN-BMIGLBTASA-N 0.000 description 11
- 229960002646 scopolamine Drugs 0.000 description 11
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 11
- 101150060184 ACHE gene Proteins 0.000 description 10
- 108090000397 Caspase 3 Proteins 0.000 description 10
- 102000003952 Caspase 3 Human genes 0.000 description 10
- 235000010288 sodium nitrite Nutrition 0.000 description 10
- 230000000144 pharmacologic effect Effects 0.000 description 9
- 210000003462 vein Anatomy 0.000 description 9
- 241000282412 Homo Species 0.000 description 8
- 102000003810 Interleukin-18 Human genes 0.000 description 8
- 108090000171 Interleukin-18 Proteins 0.000 description 8
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 8
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 8
- 108700000707 bcl-2-Associated X Proteins 0.000 description 8
- 102000055102 bcl-2-Associated X Human genes 0.000 description 8
- 230000002146 bilateral effect Effects 0.000 description 8
- 238000009826 distribution Methods 0.000 description 8
- 239000003651 drinking water Substances 0.000 description 8
- 235000020188 drinking water Nutrition 0.000 description 8
- 230000036541 health Effects 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 238000001543 one-way ANOVA Methods 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 230000002035 prolonged effect Effects 0.000 description 8
- 238000007619 statistical method Methods 0.000 description 8
- 231100000027 toxicology Toxicity 0.000 description 8
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 7
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 7
- 206010012289 Dementia Diseases 0.000 description 7
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 7
- 102000004889 Interleukin-6 Human genes 0.000 description 7
- 108090001005 Interleukin-6 Proteins 0.000 description 7
- 230000002159 abnormal effect Effects 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 239000002552 dosage form Substances 0.000 description 7
- 238000011534 incubation Methods 0.000 description 7
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 7
- 241000208340 Araliaceae Species 0.000 description 6
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 6
- 235000003140 Panax quinquefolius Nutrition 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 230000017531 blood circulation Effects 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 235000008434 ginseng Nutrition 0.000 description 6
- 230000000971 hippocampal effect Effects 0.000 description 6
- 229920003023 plastic Polymers 0.000 description 6
- 240000006079 Schisandra chinensis Species 0.000 description 5
- 235000008422 Schisandra chinensis Nutrition 0.000 description 5
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 5
- 230000006399 behavior Effects 0.000 description 5
- 210000000653 nervous system Anatomy 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- 238000003860 storage Methods 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 238000010156 Dunnett's T3 test Methods 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 230000003542 behavioural effect Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 238000001647 drug administration Methods 0.000 description 4
- 238000013401 experimental design Methods 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 230000036449 good health Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 230000003340 mental effect Effects 0.000 description 4
- 238000001422 normality test Methods 0.000 description 4
- 230000007170 pathology Effects 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- 208000003950 B-cell lymphoma Diseases 0.000 description 3
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 3
- 206010051602 Laziness Diseases 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 208000009205 Tinnitus Diseases 0.000 description 3
- 229960004373 acetylcholine Drugs 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 230000003925 brain function Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000007596 consolidation process Methods 0.000 description 3
- 229910052802 copper Inorganic materials 0.000 description 3
- 239000010949 copper Substances 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 208000002173 dizziness Diseases 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- 235000012631 food intake Nutrition 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 238000007654 immersion Methods 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 230000006386 memory function Effects 0.000 description 3
- 230000007334 memory performance Effects 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 229960004499 scopolamine hydrobromide Drugs 0.000 description 3
- WTGQALLALWYDJH-MOUKNHLCSA-N scopolamine hydrobromide (anhydrous) Chemical compound Br.C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 WTGQALLALWYDJH-MOUKNHLCSA-N 0.000 description 3
- 230000001568 sexual effect Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 229910001220 stainless steel Inorganic materials 0.000 description 3
- 239000010935 stainless steel Substances 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- 231100000886 tinnitus Toxicity 0.000 description 3
- 210000001835 viscera Anatomy 0.000 description 3
- 238000010792 warming Methods 0.000 description 3
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 2
- 201000004384 Alopecia Diseases 0.000 description 2
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 2
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 2
- 208000004736 B-Cell Leukemia Diseases 0.000 description 2
- 241000721047 Danaus plexippus Species 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- -1 IL-1β Proteins 0.000 description 2
- 208000034819 Mobility Limitation Diseases 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 208000032140 Sleepiness Diseases 0.000 description 2
- 206010041349 Somnolence Diseases 0.000 description 2
- 230000006933 amyloid-beta aggregation Effects 0.000 description 2
- 210000000702 aorta abdominal Anatomy 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000036770 blood supply Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 2
- 229960002327 chloral hydrate Drugs 0.000 description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- 230000019771 cognition Effects 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 230000000674 effect on sodium Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 208000024963 hair loss Diseases 0.000 description 2
- 230000003676 hair loss Effects 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 208000027906 leg weakness Diseases 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 231100000863 loss of memory Toxicity 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000002398 materia medica Substances 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 210000002682 neurofibrillary tangle Anatomy 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 235000021062 nutrient metabolism Nutrition 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 210000003625 skull Anatomy 0.000 description 2
- 230000037321 sleepiness Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 108010022752 Acetylcholinesterase Proteins 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 241000336316 Cistanche tubulosa Species 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- TULNGKSILXCZQT-UHFFFAOYSA-N Cysteinyl-Aspartate Chemical compound SCC(N)C(=O)NC(C(O)=O)CC(O)=O TULNGKSILXCZQT-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 208000027534 Emotional disease Diseases 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010054949 Metaplasia Diseases 0.000 description 1
- 108010061951 Methemoglobin Proteins 0.000 description 1
- 102000009664 Microtubule-Associated Proteins Human genes 0.000 description 1
- 108010020004 Microtubule-Associated Proteins Proteins 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- 239000008118 PEG 6000 Substances 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 1
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 239000005708 Sodium hypochlorite Substances 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 101710086987 X protein Proteins 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 229940022698 acetylcholinesterase Drugs 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 238000013475 authorization Methods 0.000 description 1
- 208000019804 backache Diseases 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 229960002233 benzalkonium bromide Drugs 0.000 description 1
- KHSLHYAUZSPBIU-UHFFFAOYSA-M benzododecinium bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 KHSLHYAUZSPBIU-UHFFFAOYSA-M 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 238000010876 biochemical test Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004004 carotid artery internal Anatomy 0.000 description 1
- 229960002152 chlorhexidine acetate Drugs 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 229940109275 cyclamate Drugs 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 210000001951 dura mater Anatomy 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 239000010642 eucalyptus oil Substances 0.000 description 1
- 229940044949 eucalyptus oil Drugs 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000002309 gasification Methods 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 208000037805 labour Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000015689 metaplastic ossification Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 210000004088 microvessel Anatomy 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- ZAOCWQZQPKGTRN-UHFFFAOYSA-N nitrous acid;sodium Chemical compound [Na].ON=O ZAOCWQZQPKGTRN-UHFFFAOYSA-N 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- MCSINKKTEDDPNK-UHFFFAOYSA-N propyl propionate Chemical compound CCCOC(=O)CC MCSINKKTEDDPNK-UHFFFAOYSA-N 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000003087 receptor blocking agent Substances 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 208000037921 secondary disease Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 230000003867 tiredness Effects 0.000 description 1
- 208000016255 tiredness Diseases 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 230000005068 transpiration Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 210000002385 vertebral artery Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/64—Orobanchaceae (Broom-rape family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/254—Acanthopanax or Eleutherococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9062—Alpinia, e.g. red ginger or galangal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Definitions
- the invention relates to a clinically experienced drug for treating senile dementia. It explores the pathogenesis and treatment of senile dementia from "deficiency of kidney essence", and obtains obvious curative effect in clinical application. It belongs to the application field of traditional Chinese medicine.
- Senile dementia belongs to the category of "dementia”, “forgetfulness”, and “dementia” in traditional Chinese medicine. Clinically, it is characterized by mental decline and forgetfulness. Lonely and widowed, emotional disorders, etc., from the diseased viscera, the kidney, spleen, and heart are more responsible, involving the pathogenesis of essence, qi, blood, phlegm, stagnation, and stasis. Blood is weak, blood stays as stasis, blood stasis blocks Qi, stagnation of Qi leads to phlegm confusion, phlegm and blood stasis cementation, brain network blockage, and dementia due to failure of clear orifices.
- senile dementia mostly occurs in the elderly, and the progress of the disease is closely related to age.
- the key pathogenesis of aging is the loss of essence, the lack of kidney essence, the gradual emptying of the marrow sea, the loss of the brain, and the failure of the mind. It is of great significance and value to explore the pathogenesis and pathogenesis of senile dementia from deficiency of essence.
- collaterals are divided into the qi collaterals that run the meridian qi and the veins that run the blood, which respectively play the normal physiological functions of "qi governs the warming, and blood governs the moistening".
- "Thousands of Gold Prescriptions” said: “The head is the head of the body, injected by the human spirit, the qi and blood are shrewd, and the three hundred and sixty-five collaterals all return to the head", pointing out the close connection between the collaterals and the brain.
- the qi collaterals of the brain play the role of warming and nourishing, information transmission, and regulation and control, covering the thinking, movement, and language functions of the brain's high-level central nervous system; Function, covering all levels of small and medium blood vessels and microvessels branched from the vertebral artery and internal carotid artery throughout the brain, especially the microcirculation.
- the normal cognition and memory function of the brain depends on the unobstructed collaterals. In the case of old age, the functions of the five internal organs gradually decline, the transpiration and gasification are abnormal, the body fluid cannot be transported and transported into the cloth and becomes phlegm, or the kidney essence is insufficient to transport the blood.
- the combination of phlegm and blood stasis blocks the veins, and the blockage in the qi collaterals directly causes the structure and function of the qi collaterals to be abnormal, and the brain collaterals are not nourished; the blockage in the veins, damage to the veins, accelerates the metaplasia of phlegm and blood stasis, and the phlegm stasis acts as a secondary disease.
- Pathogenic factors, blockage of veins, abnormal blood supply and blood exchange at the end of the veins will eventually cause or aggravate the damage of Qi collaterals. It can be seen that the deficiency of kidney essence and brain collaterals are the key pathogenesis of dementia. Then develop into phlegm, blood stasis block the veins, further aggravating the state of an illness.
- Another patent of the inventor, CN111939237A discloses a composition for improving memory, which is composed of Acanthopanax, Ginseng, Yizhiren, and Schisandra, but this invention is different from the treatment principle of the present invention.
- This patent uses ginseng as the main The medicine focuses on nourishing qi and promoting body fluid, and focuses on improving learning and memory impairment.
- kidney essence and insufficient marrow sea are the main pathogenesis of senile dementia.
- the treatment principle of "tonifying kidney and essence, dredging collaterals and improving intelligence" is established.
- the sea of marrow is nourished, the brain network is unobstructed, and the mental mechanism is used. It can significantly improve memory loss, slow thinking, waist and knee weakness, dizziness, tinnitus, tiredness, frequent urination and other symptoms caused by kidney essence deficiency.
- the treatment method is "tonifying kidney and essence, dredging collaterals and improving intelligence", taking Cistanche deserticola as monarch drug, Acanthopanax as minister drug, improving intelligence Jen is an adjuvant drug, Angelica is an envoy drug, and establishes the prescription of the pharmaceutical composition of the present invention.
- Monarch drug Herba Cistanche, sweet, sour, salty, warm, enters the kidney meridian.
- Herba Cistanche, sweet, sour, salty, warm enters the kidney meridian.
- Adjuvant medicine Yizhiren, pungent, warm, enter the spleen, kidney meridian. Tonify the kidney and solidify the essence, promote yang and recede yin, nourish the deficiency of kidney essence, warm the kidney and consolidate essence, store and return to the source, and have obvious effects on mental decline caused by deficiency of kidney essence, forgetful things, laziness and sleepiness. The effect of filling essence and marrow, nourishing essence and strengthening kidney.
- Angelica warm in nature, sweet and pungent, Guixin, liver, spleen meridian, nourishes blood and blood, moistens dryness and smoothes intestines, enters the blood without authorization, as an envoy, introduces various medicines into the collaterals
- Angelica can not only nourish blood, but also activate blood , not only can stimulate the meridian, but also activate the collaterals, tonify the movement, and tonic, it is an important medicine in the blood, cooperate with Acanthopanax to strengthen the effect of promoting blood circulation and dredging collaterals, leading various medicines into the blood, promoting blood circulation to dredge collaterals, to Elderly and infirm patients have a better effect on improving their symptoms of forgetfulness and insomnia.
- the pharmaceutical composition of the present invention is aimed at the basic pathogenesis change of senile dementia kidney essence deficiency, and pays attention to replenishing kidney essence in treatment, dredging collaterals and improving intelligence.
- Acanthopanax senticosus is supplemented with the prenatal and postnatal days, and at the same time, it is supplemented with Yizhi Renzi to nourish the kidney essence.
- the combination of Angelica and Acanthopanax senticosus is used to promote blood circulation and dredge collaterals.
- Forgetfulness and other dementia manifestations can also significantly improve the general clinical symptoms of senile dementia patients caused by kidney essence deficiency such as dizziness, tinnitus, tooth shaking and hair loss, backache and leg weakness, difficulty walking, laziness and sleepiness, etc., and improve the quality of life.
- composition consists of the following Chinese medicinal materials in parts by weight:
- Cistanche 200-600 parts Cistanche 200-600 parts, Acanthopanax 400-1200 parts, Yizhiren 200-600 parts, Angelica 200-600 parts.
- composition is preferably made of the following raw materials in parts by weight:
- Cistanche 300-500 parts Cistanche 300-500 parts, Acanthopanax 600-1000 parts, Yizhiren 300-500 parts, Angelica 300-500 parts.
- composition is preferably made of the following raw materials in parts by weight:
- Cistanche 400 parts Cistanche 400 parts, Acanthopanax 800 parts, Yizhiren 400 parts, Angelica 400 parts.
- composition is preferably made of the following raw materials in parts by weight:
- Cistanche 380 parts Cistanche 380 parts, Acanthopanax 700 parts, Yizhiren 400 parts, Angelica 500 parts.
- composition is preferably made of the following raw materials in parts by weight:
- Cistanche 600 parts Cistanche 600 parts, Acanthopanax 400 parts, Yizhiren 500 parts, Angelica 500 parts.
- composition of the present invention comprises the following steps:
- step (4) gained thick extract and dry, pulverize, gained dry paste powder and volatile oil constitute the active component of pharmaceutical composition of the present invention jointly.
- Cistanche described in the composition is Cistanche tubulosa.
- the dosage form that the pharmaceutical composition can be prepared into is capsule, tablet, pill, powder or ointment.
- Described tablet preparation method is:
- step (6) Mix the dry cream powder in step (4) with the fine powder in step (5), add auxiliary materials, and prepare it into tablets.
- the invention also provides the application of the composition in improving memory impairment medicine.
- the present invention also provides the application of the composition in improving cholinergic system function, alleviating oxidative stress damage, reducing nerve cell apoptosis or inhibiting inflammatory response.
- composition of the present invention the Latin name and the processing method thereof of the bulk drug as the active component are from “Chinese Medicine Encyclopedia” (July, 1977, first edition, Shanghai Science and Technology Press) and “Chinese Pharmacopoeia” (2005 edition) , Chemical Industry Press).
- the pharmaceutical composition of the present invention can be made into any pharmaceutically acceptable conventional dosage form according to the conventional preparation process, for example, the preparation process recorded in Fan Biting's "Chinese Medicine Pharmacy” (Shanghai Science Press, December 1997, 1st edition), such as Capsules, tablets, pills, powders, soft capsules or ointments, etc.
- the pharmaceutical composition is one of capsules, tablets, pills, powders, soft capsules or ointment preparations.
- pharmaceutically acceptable ingredients such as fillers, disintegrants, lubricants, suspending agents, binders, sweeteners, flavoring agents, preservatives, bases, etc.
- Fillers include: starch, pregelatinized starch, lactose, mannitol, chitin, microcrystalline cellulose, sucrose, etc.; disintegrants include: starch, pregelatinized starch, microcrystalline cellulose, sodium carboxymethyl starch, Cross-linked polyvinylpyrrolidone, low-substituted hydroxypropyl cellulose, croscarmellose sodium, etc.; lubricants include: magnesium stearate, sodium lauryl sulfate, talc, silicon dioxide, etc.; suspending agent Including: polyvinylpyrrolidone, microcrystalline cellulose, sucrose, agar, hydroxypropylmethylcellulose, etc.; binders include starch slurry, polyvinylpyrrolidone, hydroxypropylmethylcellulose, etc.; sweeteners include: Sodium saccharin, aspartame, sucrose, cyclamate, glycyrrhetinic acid, etc.; flavoring agents include:
- the treatment focuses on replenishing kidney essence, dredging collaterals and improving intelligence.
- Cistanche deserticola, Acanthopanax senticosus and Acanthopanax combined with prenatal and postnatal supplements for nourishing kidney and essence are selected, and at the same time, it is supplemented with Yizhi Renzi nourishes the kidney essence, uses Angelica and Acanthopanax to promote blood circulation and dredge collaterals
- the prescription is simple and effective, not only helps to improve dementia symptoms such as mental decline and forgetfulness caused by kidney essence deficiency, but also can significantly improve the elderly
- Patients with dementia can experience systemic clinical symptoms caused by kidney essence deficiency, such as dizziness and tinnitus, teeth shaking and hair loss, waist soreness and leg weakness, difficulty walking, laziness and lying down, etc., and improve the quality of life.
- the AD model was induced by injecting A ⁇ 42 oligomers in the CA1 region of the bilateral hippocampus of rats, and the improvement effect of the pharmaceutical composition of the present invention on the learning and memory abilities of AD rats was evaluated.
- 120 animals were randomly divided into blank group, sham operation group, model group, huperzine A group, anti-brain failure group, pharmaceutical composition group 1 of the present invention, pharmaceutical composition group 2 of the present invention, control drug
- the dosage of the pharmaceutical composition group 1 of the present invention and the pharmaceutical composition group 2 of the present invention are 3.2 crude drugs/kg ⁇ day -1 , which is equivalent to 8 times the clinical human dose, and A ⁇ 42 is injected into the CA1 region of the bilateral hippocampus.
- Oligomer modeling 1 week after modeling, animals were administered orally according to body weight, water maze test was performed after 3 weeks, bilateral hippocampus was taken after 5 weeks, hippocampal ACHE, SOD, MDA and serum SOD, MDA were detected biochemically, and A ⁇ was detected by Western blot , Tau, p-Tau, Bcl-2, Bax, Caspase-3, IL-6, IL-1 ⁇ , IL-18, TNF- ⁇ . [Result] 1.
- Oxidative stress index results although the pharmaceutical composition group 1 of the present invention, the pharmaceutical composition group 2 of the present invention, and the hippocampus MDA content of the control group have no significant difference compared with the model group (P>0.05), they show a decreasing trend. 4.
- the expression of A ⁇ in the pharmaceutical composition group 1 of the present invention, the pharmaceutical composition group 2 of the present invention, and the control drug group was significantly lower than that of the model group (P ⁇ 0.01). 5.
- the expression of p-Tau in the pharmaceutical composition group 1 of the present invention, the pharmaceutical composition group 2 of the present invention, and the control drug group was significantly lower than that of the model group (P ⁇ 0.01 or P ⁇ 0.05). 6.
- composition group 1 of the present invention pharmaceutical composition group 2 of the present invention, contrast drug group Caspase-3 expression significantly reduces (P ⁇ 0.01) than model group;
- Pharmaceutical composition group 1 of the present invention, this invention The ratio of 2Bcl-2/Bax in the inventive pharmaceutical composition group was significantly higher than that in the model group (P ⁇ 0.01 or P ⁇ 0.05).
- Inflammation index results the pharmaceutical composition group 1 of the present invention, the pharmaceutical composition group 2 of the present invention, and the expression of IL-6, IL-1 ⁇ , IL-18, TNF- ⁇ in the control group were significantly reduced compared with the model group (P ⁇ 0.01 or P ⁇ 0.05).
- the pharmaceutical composition group 1 of the present invention, the pharmaceutical composition group 2 of the present invention, and the control drug group have obvious improvement effects on the learning and memory abilities of AD rats induced by A ⁇ 42 oligomers, and their effects may be related to improving the cholinergic system. function, reducing oxidative stress damage, reducing nerve cell apoptosis, and inhibiting inflammatory response.
- Bcl-2 B cell lymphoma/lewkmia-2 B cell lymphoma/leukemia-2
- the AD model is induced by injecting A ⁇ 42 oligomers into the CA1 region of the bilateral hippocampus of rats, and the improvement effect of the pharmaceutical composition of the present invention on the learning and memory abilities of AD rats is evaluated.
- composition 1 of the present invention abbreviation: RJYZ1, pharmaceutical composition 2 of the present invention, abbreviation: RJYZ2, control drug, the contents of capsules prepared according to Example 1 of CN111939237A patent.
- Source and batch number Source: Hebei Yiling Hospital, batch number: 20150406.
- a ⁇ 42 oligomer provided by the Institute of Biological Science and Technology, School of Science, Beijing Jiaotong University.
- Anti-brain failure capsule Shijiazhuang No.4 Medicine Co., Ltd., batch number: KN15031001.
- SOD detection kit Nanjing Jiancheng Institute of Bioengineering, batch number: 20150821.
- MDA detection kit Nanjing Jiancheng Institute of Bioengineering, batch number: 20150826.
- ACHE detection kit Nanjing Jiancheng Institute of Bioengineering, batch number: 20150820.
- BCA protein quantification kit Beijing Suo Laibao Technology Co., Ltd., batch number: 20151015.
- a ⁇ primary antibody abcam, batch number: ab39377.
- Tau primary antibody abcam, batch number: ab32057.
- p-Tau primary antibody abcam, lot number: ab131354.
- Bcl-2 primary antibody abcam, lot number: ab7973.
- Bax primary antibody abcam, lot number: ab7977.
- Caspase-3 primary antibody abcam, lot number: ab44976.
- IL-6 primary antibody abcam, batch number: ab83339.
- IL-1 ⁇ primary antibody abcam, batch number: ab9722.
- IL-18 primary antibody abcam, batch number: ab191860.
- TNF- ⁇ primary antibody abcam, batch number: ab6671.
- the quarantine period for new animals is 5 days. During the quarantine period, the animals drink water and eat normally, are in good health, and have no signs of disease or death.
- Drinking water fill with ordinary water for animals to drink freely, rinse the drinking water bottle and change the water once a day.
- RJYZ1, RJYZ2, and control drug group are intended to use 24.0 g of crude drug per day, and calculated based on a body weight of 60 kg, the proposed clinical dose is 0.4 g of crude drug/kg.
- the content is 5.0g crude drug/g dry cream powder, batch number 20150406.
- Rats were randomly divided into 8 groups according to body weight, namely, blank group, sham operation group, model group, huperzine A group, anti-brain failure group, RJYZ1 group, RJYZ2 group, and control drug group.
- Crude drug/kg ⁇ day -1 equivalent to 8 times the clinical human dose
- the maximum clinical daily dose of huperzine A (9 tablets) is 450 ⁇ g/person
- the maximum clinical daily dose of anti-brain failure capsules (18 capsules) is 32.02g
- Crude drug/human, rat administration dose is 8 times the clinical maximum daily dose, respectively 60 ⁇ g/kg ⁇ day -1 and 4.3g crude drug/kg ⁇ day -1 . See Table 1.
- Oral administration is consistent with the clinically recommended oral route.
- test drug was prepared with distilled water to the concentration used in the experiment (see Table 1). After preparation, it was stored at 2-8°C for future use. The positive drug was prepared immediately after use.
- Animals were given intragastric administration of 10ml/kg, and distilled water was given to the blank, sham-operated and model groups, once a day for 5 consecutive weeks.
- the bilateral hippocampal CA1 area as the injection site, and the positioning coordinates: 3.5mm behind the bregma, 2.1mm on both sides of the midline, 3.6 mm below the dura mater, drill the skull with a dental drill circularly at the coordinate point, slowly insert the needle vertically to the target point, then inject 5 ⁇ l (1 ⁇ g/ ⁇ l) A ⁇ 42 oligomer at a constant speed and slowly, the injection time is 5 minutes, and the needle is retained for 3 minutes , and then slowly withdraw the needle for 3 minutes to ensure that the solution was fully diffused.
- the sham operation group was given the same amount of normal saline, and the rest of the operations were the same as before. A little penicillin powder was given to the skin incision and the incision was sutured.
- the water maze experiment is mainly used to test the ability of experimental animals to learn and remember spatial positions. It consists of a circular pool, a platform and a video tracking system. The circular pool is divided into four quadrants. This time involved two tests, including positioning navigation test (4d) and space exploration test (1d).
- Positioning navigation test fix the platform at the center of the first quadrant 2cm below the water, control the water temperature at 22-26°C, choose two water entry points at the opposite side of the platform away from the platform, and place the animals facing the pool wall Gently put it into the water, and set the maximum swimming time to 90s. If the rat finds the platform within 90s, let it stay on the platform for 10s. On the 4th day, the average time (escape latency) and the total distance of the rats in each group to find the platform from the two water entry points were recorded.
- Rats were anesthetized, abdominal aorta blood was collected and centrifuged to obtain serum, blood was prepared for biochemical testing, bilateral hippocampus was collected on ice, and stored in liquid nitrogen, 3 animals were prepared for Western blot testing, and the rest were homogenized for tissue biochemical testing.
- Biochemical detection of hippocampal tissue ACHE, SOD, MDA.
- the experimental data is analyzed and processed by SPSS11.5 statistical software, and the statistical results are expressed as mean ⁇ standard deviation It means that the normality test is carried out first, and the data conforming to the normal distribution are compared with one-way analysis of variance (One-Way ANOVA). If the variances are equal, the least significant difference method (LSD) is used for pairwise comparison. For Qi, the Dunnett's T3 test was used for pairwise comparison; if the normal distribution was not met, the non-parametric test was used for statistical analysis.
- LSD least significant difference method
- RJYZ can significantly improve the learning and memory ability of AD rats induced by A ⁇ 42 oligomers, which may be through reducing the activity of ACHE and improving the function of cholinergic system; reducing the oxidative stress damage caused by the increase of MDA content in the hippocampus; reducing A ⁇ deposition in the hippocampus; reduce neurofibrillary tangles caused by overexpression of p-Tau in the hippocampus; reduce the expression of caspase-3, increase the ratio of anti-apoptotic Bcl-2/Bax, reduce nerve cell apoptosis; inhibit the inflammatory factor IL -6, IL-1 ⁇ , IL-18, TNF- ⁇ expression, reducing inflammatory response.
- the platform jumping test training was started 1 hour after the last administration, and the training was carried out for 5 minutes. After 24 hours, the memory scores were tested.
- the model group and each drug group were given 30 minutes before the test. 40% ethanol 10ml/kg was given by intragastric administration, and the corresponding volume of distilled water was intragastrically administered to the mice in the blank group. The latency period and the number of mistakes of jumping off the platform for the first time within 5 minutes were observed and recorded as memory indicators. ⁇ Result ⁇ Compared with the blank group, the incubation period of the mice in the model group was significantly shortened (P ⁇ 0.05), and the number of mistakes was significantly increased (P ⁇ 0.01).
- the mouse model of memory loss caused by ethanol is used to observe the improvement effect of the pharmaceutical composition of the present invention on the learning and memory ability of the memory loss mouse.
- test product (same as test 1 test product)
- the quarantine period for new animals is 3 days. During the quarantine period, the animals drink water and eat normally, are in good health, and have no signs of disease or death.
- Drinking water fill with ordinary water for animals to drink freely, rinse the drinking water bottle and change the water once a day.
- RJYZ Information provided by the entrusting unit: RJYZ’s proposed clinical dosage for humans is 24.0g of crude drug/day, calculated on the basis of 60kg body weight, the proposed clinical dosage is 0.4g of crude drug/kg, and the content of the dry ointment powder of the test product is 5.0g of crude drug/day g dry cream powder, batch number 20150406.
- mice were randomly divided into 6 groups according to body weight, namely blank group, model group, positive drug (huperzine A) group, RJYZ1 group, RJYZ2 group, control drug group, 12 in each group, RJYZ1 group, RJYZ2 group, control drug group
- the group is planned to be 4.0 crude drug/kg ⁇ day -1 , which is equivalent to 10 times the clinical human dose.
- the maximum clinical daily dose of huperzine A (9 tablets) is 450 ⁇ g/person/day, and the dose for mice is the clinical maximum daily dose. 10 times the dosage, that is, 75 ⁇ g/kg ⁇ day -1 . See Table 5.
- Oral administration is consistent with the clinically recommended oral route.
- the distilled water of each test drug was prepared to the experimental concentration (see Table 5), and after preparation, it was stored at 2-8°C for future use, and the positive drug was prepared immediately after use.
- Animals were given intragastric administration of 10ml/kg, and the blank group and model group were given distilled water, once a day for 10 consecutive days.
- the mouse jumping platform device consists of six rectangular reflection boxes with a size of 32cm*22.5cm*33cm. They are divided into 6 rooms with black plastic plates. The bottom surface is a stainless steel grid with a grid spacing of 0.5cm. And a rubber platform with a diameter of 4.5cm, place the mouse on the platform gently facing the corner, adapt to the environment for 3 minutes, and then pass a 36V current. If the animal jumps off the platform, it will be shocked. Its normal reaction should be to jump back to the platform to avoid injury sexual stimulation, most animals may jump to the grid again or several times to escape the electric shock. When jumping, the mouse’s feet touch the copper grid at the same time as the electric shock, which is regarded as the number of errors. After training for 5 minutes, test it after 24 hours, which is memory. Keep the test, record the latency and the number of mistakes when jumping off the platform for the first time within 5 minutes.
- Newly received animals were labeled and quarantined for 3 days. After the quarantine was completed, the animals were randomly divided into 6 groups according to body weight, as described above. Oral administration according to body weight, once a day, for 10 consecutive days, distilled water was given to the blank group and the model group, platform training was started 1 hour after the last administration, and the training was performed for 5 minutes, and memory scores were tested after 24 hours. In the first 30 minutes, 40% ethanol 10ml/kg was given by intragastric administration, and the corresponding volume of distilled water was administered to the mice in the blank group. The latency period and the number of mistakes for the first jump off the platform within 5 minutes were observed and recorded, and the platform jump latency of the mice that did not jump off the platform within 5 minutes Calculated by 300s.
- the experimental data is analyzed and processed by SPSS11.5 statistical software, and the statistical results are expressed as mean ⁇ standard deviation It means that firstly, the normality test is carried out, and the data conforming to the normal distribution are compared with one-way analysis of variance (One-WayANOVA). If the variances are equal, the least significant difference method (LSD) is used for pairwise comparison. The Dunnett's T3 test was used for pairwise comparison; if the normal distribution was not met, the non-parametric test was used for statistical analysis.
- Impairment of learning and memory is an important manifestation of senile dementia, and it is one of the important brain functions that are indispensable for the survival of humans and animals.
- Learning is the process by which the nervous system accepts changes in the external environment to acquire new behaviors and experiences.
- Memory is the experience after learning. maintenance and reproduction.
- learning and memory are divided into three stages, that is, acquisition, consolidation and reproduction.
- Ethanol is a central nervous system inhibitor, and it is a commonly used tool drug for memory and reproduction loss models. It can inhibit the conditioned reflex process of animals and make protein and RNA in the brain Synthesis is blocked, and systems such as cholinergic and dopamine are altered, thereby disrupting learning and memory functions.
- Platform jumping test is a commonly used behavioral method for testing learning and memory, but its accuracy is easily affected by many factors, such as experimental environment, experimental animals, non-specific interference, reward and punishment effects, etc.
- the sodium nitrite-induced memory consolidation disorder model is used to observe the improvement effect of the pharmaceutical composition of the present invention on the learning and memory ability of the memory consolidation disorder mice.
- test product (same as test 1 test product)
- the quarantine period for new animals is 5 days. During the quarantine period, the animals drink water and eat normally, are in good health, and have no signs of disease or death.
- Drinking water fill with ordinary water for animals to drink freely, rinse the drinking water bottle and change the water once a day.
- RJYZ Information provided by the entrusting unit: RJYZ’s proposed clinical dosage for humans is 24.0g of crude drug/day, calculated on the basis of 60kg body weight, the proposed clinical dosage is 0.4g of crude drug/kg, and the content of the dry ointment powder of the test product is 5.0g of crude drug/day g dry cream powder, batch number 20150406.
- mice were randomly divided into 6 groups according to body weight, namely blank group, model group, positive drug (huperzine A) group, RJYZ low, medium and high dose groups, 16 in each group, RJYZ1 group, RJYZ2 group, control drug group It is planned to be 4.0g crude drug/kg ⁇ day -1 , which is equivalent to 10 times the clinical human dose.
- the maximum clinical daily dose of huperzine A (9 tablets) is 450 ⁇ g/person/day, and the clinical maximum daily dose for mice is 10 times the dosage, that is, 75 ⁇ g/kg ⁇ day -1 . See Table 7.
- Oral administration is consistent with the clinically recommended oral route.
- test drug was prepared with distilled water to the concentration used in the experiment (see Table 7). After preparation, it was stored at 2-8°C for future use, and the positive drug was prepared immediately after use.
- Animals were given intragastric administration of 10ml/kg, and the blank group and model group were given distilled water, once a day for 10 consecutive days.
- the mouse jumping platform device consists of six rectangular reflection boxes with a size of 32cm*22.5cm*33cm. They are divided into 6 rooms with black plastic plates. The bottom surface is a stainless steel grid with a grid spacing of 0.5cm. And a rubber platform with a diameter of 4.5cm, place the mouse on the platform gently facing the corner, adapt to the environment for 3 minutes, and then pass a 36V current. If the animal jumps off the platform, it will be shocked. Its normal reaction should be to jump back to the platform to avoid injury sexual stimulation, most animals may jump to the grid again or several times to escape the electric shock. When jumping, the mouse’s feet touch the copper grid at the same time as the electric shock, which is regarded as the number of errors. After training for 5 minutes, test it after 24 hours, which is memory. Keep the test, record the latency and the number of mistakes when jumping off the platform for the first time within 5 minutes.
- Newly received animals were labeled and quarantined for 5 days. After the quarantine was completed, the animals were randomly divided into 6 groups according to body weight, as described above. Oral administration according to body weight, once a day, for 10 consecutive days, distilled water was given to the blank group and the model group, platform training was started 1 hour after the last administration, and the training was 5 minutes.
- mice in the blank group were given corresponding volume of normal saline, after 24 hours, the memory performance was tested, the latency period and the number of mistakes when jumping off the platform for the first time within 5 minutes were observed and recorded, and those who did not jump off within 5 minutes
- the platform jumping latency of mice is calculated as 300s.
- the experimental data is analyzed and processed by SPSS11.5 statistical software, and the statistical results are expressed as mean ⁇ standard deviation It means that the normality test is carried out first, and the data conforming to the normal distribution are compared with one-way analysis of variance (One-Way ANOVA). If the variances are equal, the least significant difference method (LSD) is used for pairwise comparison. For Qi, the Dunnett's T3 test was used for pairwise comparison; if the normal distribution was not met, the non-parametric test was used for statistical analysis.
- LSD least significant difference method
- Impairment of learning and memory is an important manifestation of senile dementia, and it is one of the important brain functions that are indispensable for the survival of humans and animals.
- Learning is the process by which the nervous system accepts changes in the external environment to acquire new behaviors and experiences.
- Memory is the experience after learning. maintenance and reproduction.
- learning and memory are divided into three stages, that is, acquisition, consolidation and reproduction. After a large amount of nitrite enters the body, normal hemoglobin can be changed into methemoglobin, which will lose the ability to carry oxygen, cause tissue hypoxia, and damage nerve cells. Can cause memory consolidation disorders in animals.
- Platform jumping test is a commonly used behavioral method for testing learning and memory, but its accuracy is easily affected by many factors, such as experimental environment, experimental animals, non-specific interference, reward and punishment effects, etc.
- test product (same as test 1 test product)
- the quarantine period for new animals is 5 days. During the quarantine period, the animals drink water and eat normally, are in good health, and have no signs of disease or death.
- Drinking water fill with ordinary water for animals to drink freely, rinse the drinking water bottle and change the water once a day.
- RJYZ Information provided by the entrusting unit: RJYZ’s proposed clinical dosage for humans is 24.0g of crude drug/day, calculated on the basis of 60kg body weight, the proposed clinical dosage is 0.4g of crude drug/kg, and the content of the dry ointment powder of the test product is 5.0g of crude drug/day g dry cream powder, batch number 20150406.
- mice were randomly divided into 6 groups according to body weight, namely blank group, model group, positive drug (huperzine A) group, RJYZ1 group, RJYZ2 group, control drug group, 16 in each group, RJYZ1 group, RJYZ2 group, control drug group
- the group is planned to be 4.0g crude drug/kg ⁇ day -1 , equivalent to 10 times the clinical human dose, the maximum clinical daily dose of huperzine A (9 tablets) is 450 ⁇ g/person/day, and the dose for mice is the clinical maximum 10 times the daily dosage, that is, 75 ⁇ g/kg ⁇ day -1 . See Table 9.
- Oral administration is consistent with the clinically recommended oral route.
- the distilled water of each test drug was prepared to the concentration used in the experiment (see Table 9), and after preparation, it was stored at 2-8°C for future use.
- Animals were given intragastric administration of 10ml/kg, and the blank group and model group were given distilled water, once a day for 10 consecutive days.
- the mouse jumping platform device consists of six rectangular reflection boxes with a size of 32cm*22.5cm*33cm. They are divided into 6 rooms with black plastic plates. The bottom surface is a stainless steel grid with a grid spacing of 0.5cm. And a rubber platform with a diameter of 4.5cm, place the mouse on the platform gently facing the corner, adapt to the environment for 3 minutes, and then pass a 36V current. If the animal jumps off the platform, it will be shocked. Its normal reaction should be to jump back to the platform to avoid injury sexual stimulation, most animals may jump to the grid again or several times to escape the electric shock. When jumping, the mouse’s feet touch the copper grid at the same time as the electric shock, which is regarded as the number of errors. After training for 5 minutes, test it after 24 hours, which is memory. Keep the test, record the latency and the number of mistakes when jumping off the platform for the first time within 5 minutes.
- Newly received animals were labeled and quarantined for 5 days. After the quarantine was completed, the animals were randomly divided into 6 groups according to body weight, as described above. Gavage administration according to body weight, once a day, for 10 consecutive days, distilled water was given to the blank group and model group, platform training was started 1 hour after the last administration, and 3 mg/kg of scopolamine hydrobromide was injected intraperitoneally into each group except the blank group 20 minutes before training , the blank group was given the corresponding volume of normal saline, trained for 5 minutes, and tested the memory score after 24 hours. Observe and record the latency and the number of mistakes when jumping off the platform for the first time within 5 minutes.
- the experimental data is analyzed and processed by SPSS11.5 statistical software, and the statistical results are expressed as mean ⁇ standard deviation It means that firstly, the normality test is carried out, and the data conforming to the normal distribution are compared with one-way analysis of variance (One-WayANOVA). If the variances are equal, the least significant difference method (LSD) is used for pairwise comparison. The Dunnett's T3 test was used for pairwise comparison; if the normal distribution was not met, the non-parametric test was used for statistical analysis.
- Impairment of learning and memory is an important manifestation of senile dementia, and it is one of the important brain functions that are indispensable for the survival of humans and animals.
- Learning is the process by which the nervous system accepts changes in the external environment to acquire new behaviors and experiences.
- Memory is the experience after learning. maintenance and reproduction.
- learning and memory are divided into three stages, namely acquisition, consolidation and reproduction.
- Scopolamine is an M choline receptor blocker, which can resist acetylcholine and can simulate reversible memory impairment caused by insufficient secretion of acetylcholine. It is a commonly used anti-senile dementia Primary screening models for drug research.
- Platform jumping test is a commonly used behavioral method for testing learning and memory, but its accuracy is easily affected by many factors, such as experimental environment, experimental animals, non-specific interference, reward and punishment effects, etc.
- a ⁇ 42 oligomer-induced learning and memory impairment model experiments in AD rats showed that both groups of RJYZ reduced the water maze latency and total distance to varying degrees, increased the number of platform crossings and the quadrant time of the platform, and reduced the ACHE activity of the hippocampus in the choline system and the content of lipid peroxidation product MDA, and reduce the expression of A ⁇ , p-Tau and related apoptosis and inflammatory factors.
- the platform jumping test results showed that RJYZ can prolong the latency and reduce the number of errors.
- RJYZ can significantly improve the learning and memory ability of A ⁇ 42 oligomer-induced AD rats, which may be related to improving the function of cholinergic system, reducing oxidative stress damage, reducing nerve cell apoptosis, and inhibiting inflammatory response .
- RJYZ can obviously improve learning and memory in animal models of memory loss, memory consolidation disorder and memory acquisition disorder.
- Cistanche 400g Acanthopanax 800g, Yizhiren 400g, Angelica 400g.
- Cistanche cistanche and Acanthopanax extract three times with 50% ethanol under reflux, each time for 2 hours, add 10 times the amount of 50% ethanol each time, filter the extract, and concentrate the filtrate under reduced pressure to a relative density of 1.05-1.10 (60°C) clear ointment, set aside;
- Cistanche 380 parts Cistanche 380 parts, Acanthopanax 700 parts, Yizhiren 400 parts, Angelica 500 parts.
- step (6) Mix the dry cream powder in step (4) with the fine powder in step (5), add auxiliary materials, and prepare it into tablets.
- Cistanche 600g Acanthopanax 400g, Yizhiren 500g, Angelica 500g.
- step (6) Mix the dry paste powder in step (4) with the fine powder in step (5), add appropriate auxiliary materials, and prepare capsules.
- Cistanche 500g Acanthopanax 600 parts, Yizhiren 500 parts, Angelica 500 parts.
- step (6) Mix the dry cream powder in step (4) with the fine powder in step (5), add auxiliary materials, and prepare into pills.
- Raw material processing take Acanthopanax, Yizhiren, and Schisandra chinensis decoction pieces, wash and set aside; Ginseng is pulverized, passed through a 80-mesh sieve, sterilized by 60 Co irradiation, and the irradiation dose is 3kGy, set aside;
- Vacuum drying adopt vacuum oven to dry, collect dry paste, for subsequent use;
- Dry paste crushing dry paste is crushed, fine powder is collected, and set aside;
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medical Informatics (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Nutrition Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
A pharmaceutical composition useful for the treatment of Alzheimer's disease and having the functions of reinforcing kidney, replenishing essence, dredging collaterals, and benefiting intelligence, wherein the pharmaceutical composition is made from the following crude drugs in parts by weight: 200-600 parts of Cistanche deserticola, 400-1200 parts of Radix Acanthopanacis Senticosi, 200-600 parts of Fructus Alpiniae Oxyphyllae, and 200-600 parts of Angelica sinensis.
Description
相关申请的交叉引用Cross References to Related Applications
本申请要求于2021年6月29日提交中国专利局的申请号为202110724744.8，发明名称为“一种治疗老年性痴呆的组合物及其制备方法”的中国专利申请的优先权，这些申请的全部内容通过引用结合在本申请中。This application claims the priority of the Chinese patent application with the application number 202110724744.8 submitted to the China Patent Office on June 29, 2021, and the title of the invention is "a composition for treating senile dementia and its preparation method". All of these applications The contents are incorporated by reference in this application.
本发明涉及一种治疗老年性痴呆临床经验用药，从“肾精亏虚”探讨老年性痴呆病机及治疗，在临床应用中取得了明显疗效。属于中医药应用领域。The invention relates to a clinically experienced drug for treating senile dementia. It explores the pathogenesis and treatment of senile dementia from "deficiency of kidney essence", and obtains obvious curative effect in clinical application. It belongs to the application field of traditional Chinese medicine.
老年性痴呆属于中医“痴呆”、“善忘”、“呆病”等范畴，临床以智能减退，遇事多忘为临床特征，既往论及该病多因年老体衰、劳欲过度、孤独寡居、情志失调等所致，从病变脏腑多责之于肾、脾、心，涉及精、气、血、痰、郁、瘀等病机，认为年老体弱气虚血少，气运血无力，血停留为瘀，血瘀阻滞气机，气郁则痰迷，痰瘀胶结、脑络不通，清窍失灵而为痴呆。然而老年性痴呆多发生于老年人，且病程进展与年龄密切相关，年高精亏，肾精乏源、髓海渐空、脑失所养、神机失用为其关键病机，因此从肾精亏虚探讨老年性痴呆的发病和病机具有重要意义和价值。Senile dementia belongs to the category of "dementia", "forgetfulness", and "dementia" in traditional Chinese medicine. Clinically, it is characterized by mental decline and forgetfulness. Lonely and widowed, emotional disorders, etc., from the diseased viscera, the kidney, spleen, and heart are more responsible, involving the pathogenesis of essence, qi, blood, phlegm, stagnation, and stasis. Blood is weak, blood stays as stasis, blood stasis blocks Qi, stagnation of Qi leads to phlegm confusion, phlegm and blood stasis cementation, brain network blockage, and dementia due to failure of clear orifices. However, senile dementia mostly occurs in the elderly, and the progress of the disease is closely related to age. The key pathogenesis of aging is the loss of essence, the lack of kidney essence, the gradual emptying of the marrow sea, the loss of the brain, and the failure of the mind. It is of great significance and value to explore the pathogenesis and pathogenesis of senile dementia from deficiency of essence.
中医络病理论认为，络脉分为运行经气的气络和运行血液的脉络，分别发挥着“气主煦之，血主濡之”的正常生理功能。《千金要方》中言：“头者，身之元首，人神所注，气血精明，三百六十五络，皆上归于头”，指出络脉与脑的密切联系。脑之气络发挥温煦充养、信息传导、调节控制作用，涵盖了大脑高级中枢神经之思维、运动、语言功能在内；脑之脉络则发挥着供血供气、津血互换、营养代谢的功能，涵盖了从椎动脉和颈内动脉分出的遍布脑部的各级中小血管、微血管，特别是微循环。脑神认知和记忆功能正常，有赖于络脉通畅，若年老精衰，五脏功能渐退，蒸腾气化失常，津液不能运化输布而为痰浊，或肾精化气不足运血无力则血脉瘀阻，痰瘀互结滞留致络脉不通，损脑伤神，脑髓失养枯萎而加重神明失常。《灵枢·九针论》言：“人之所以成生者，血脉也。”说明脉络末端发挥着供血供气、津血互换、营养代谢的功能，血脉畅通，则气络功能得以正常发挥，脑神认知和记忆功能正常，《灵枢·平人绝谷》谓：“血脉和利，精神乃居。”肾藏元精，化生元气，若年老体衰，元气不足，络气亏少，则运血无力，脉络失畅，正如王清任所云：“元气既虚，必不能达于血管，血管 无气，必停留为瘀。”《读医随笔·承制生化论》也明确指出：“气虚不足以推血，则血必有瘀”。指出了气虚推运无力或温煦无力，其末端供血供气、津血互换、营养代谢的功能失常，痰为津凝，瘀为血滞，津血同源，痰瘀相关，故可进一步形成痰、瘀交结在一起阻滞脉道，阻塞于气络直接造成气络的结构和功能失常，脑络失养；阻塞于脉络，脉络损伤，加快痰瘀的化生，痰瘀作为继发性致病因素，阻塞脉道，脉络末端供血供气、津血互换功能失常，最后也会造成或加重气络的损伤，可见肾精元气亏虚、脑络失养是痴呆的关键病机，继而发展成痰、瘀阻滞脉络，进一步加重病情。According to the theory of collateral disease in traditional Chinese medicine, the collaterals are divided into the qi collaterals that run the meridian qi and the veins that run the blood, which respectively play the normal physiological functions of "qi governs the warming, and blood governs the moistening". "Thousands of Gold Prescriptions" said: "The head is the head of the body, injected by the human spirit, the qi and blood are shrewd, and the three hundred and sixty-five collaterals all return to the head", pointing out the close connection between the collaterals and the brain. The qi collaterals of the brain play the role of warming and nourishing, information transmission, and regulation and control, covering the thinking, movement, and language functions of the brain's high-level central nervous system; Function, covering all levels of small and medium blood vessels and microvessels branched from the vertebral artery and internal carotid artery throughout the brain, especially the microcirculation. The normal cognition and memory function of the brain depends on the unobstructed collaterals. In the case of old age, the functions of the five internal organs gradually decline, the transpiration and gasification are abnormal, the body fluid cannot be transported and transported into the cloth and becomes phlegm, or the kidney essence is insufficient to transport the blood. Then blood stasis, phlegm and blood stasis intertwine and stagnate cause collateral channels to block, damage the brain and disturb the mind, and the brain marrow loses nourishment and withers and aggravates the abnormality of the mind. "Lingshu·Nine Needles Theory" says: "The reason why people become alive is the blood." It shows that the end of the veins plays the role of supplying blood and gas, exchanging fluid and blood, and nutrient metabolism. If the brain and spirit cognition and memory functions are normal, "Lingshu·Pingren Juegu" says: "The blood is harmonious, and the spirit is the home." The kidney stores the essence and transforms the vitality. If Qi is deficient, the blood circulation will be weak and the veins will be unsmooth, just as Wang Qingren said: "If the vitality is deficient, it will not reach the blood vessels, and if the blood vessels have no Qi, they will stay as stasis." It is clearly pointed out: "Qi deficiency is not enough to push blood, then blood must have stasis." It points out that qi deficiency is weak in pushing and transporting or warming, and its terminal blood supply and gas supply, fluid and blood exchange, and nutrient metabolism are dysfunctional. Phlegm is fluid coagulation, and stasis is blood stagnation. The combination of phlegm and blood stasis blocks the veins, and the blockage in the qi collaterals directly causes the structure and function of the qi collaterals to be abnormal, and the brain collaterals are not nourished; the blockage in the veins, damage to the veins, accelerates the metaplasia of phlegm and blood stasis, and the phlegm stasis acts as a secondary disease. Pathogenic factors, blockage of veins, abnormal blood supply and blood exchange at the end of the veins, will eventually cause or aggravate the damage of Qi collaterals. It can be seen that the deficiency of kidney essence and brain collaterals are the key pathogenesis of dementia. Then develop into phlegm, blood stasis block the veins, further aggravating the state of an illness.
依据上述病因病机，以补肾填精论治该病，加之通络益智对于准确把握其病机规律具有重要意义。Based on the above-mentioned etiology and pathogenesis, it is of great significance to accurately grasp the law of its pathogenesis by treating the disease by nourishing the kidney and replenishing essence, and dredging collaterals and improving intelligence.
发明人的另一项专利CN111939237A公布了一种辅助改善记忆的组合物，由刺五加，人参，益智仁，五味子组成，但该发明与本发明的治疗原则不同，该专利以人参为君药，侧重于益气生津，重点在改善学习和记忆障碍。Another patent of the inventor, CN111939237A, discloses a composition for improving memory, which is composed of Acanthopanax, Ginseng, Yizhiren, and Schisandra, but this invention is different from the treatment principle of the present invention. This patent uses ginseng as the main The medicine focuses on nourishing qi and promoting body fluid, and focuses on improving learning and memory impairment.
发明内容Contents of the invention
鉴于上述认识，肾精亏虚、髓海不足是老年性痴呆的主要病机，确立“补肾填精、通络益智”的治疗原则，通过填补肾精以固其本，使得肾精充足，髓海得养，脑络通畅，神机得用，可明显改善肾精亏虚所致记忆减退，思维迟钝，腰膝酸软，头目眩晕，耳鸣，倦怠思卧，夜尿频数等诸症。In view of the above understanding, the deficiency of kidney essence and insufficient marrow sea are the main pathogenesis of senile dementia. The treatment principle of "tonifying kidney and essence, dredging collaterals and improving intelligence" is established. The sea of marrow is nourished, the brain network is unobstructed, and the mental mechanism is used. It can significantly improve memory loss, slow thinking, waist and knee weakness, dizziness, tinnitus, tiredness, frequent urination and other symptoms caused by kidney essence deficiency.
依据老年性痴呆“肾精亏虚、髓海不足”的中医病机特点，以“补肾填精、通络益智”为治法，以肉苁蓉为君药，刺五加为臣药，益智仁为佐药，当归为使药，确立本发明药物组合物的组方。According to the TCM pathogenesis characteristics of senile dementia "deficiency of kidney essence and insufficient marrow sea", the treatment method is "tonifying kidney and essence, dredging collaterals and improving intelligence", taking Cistanche deserticola as monarch drug, Acanthopanax as minister drug, improving intelligence Jen is an adjuvant drug, Angelica is an envoy drug, and establishes the prescription of the pharmaceutical composition of the present invention.
君药：肉苁蓉，甘酸咸，温，入肾经。首见于《神农本草经》，谓其“主五劳七伤，补中……养五脏，理阴，益精气”，具有补肾填精益髓，肉苁蓉填补肾精，温而不热，补而不峻，暖而不燥，以此为君，取其滋填肾精、从容温润之性，使髓海得养，神机得用。Monarch drug: Herba Cistanche, sweet, sour, salty, warm, enters the kidney meridian. First seen in "Shen Nong's Materia Medica", it is said that it "maintains the five labors and seven injuries, nourishes the middle... nourishes the five internal organs, regulates yin, and nourishes essence and qi". Not steep, warm but not dry, take this as the king, take it as the king, take it as nourishment and fill the kidney essence, calm and moist, so that the marrow sea can be nourished and the spirit can be used.
臣药：刺五加，辛、微苦，温，入脾、肾、心经。补肾健脾益气养神，见于《神农本草经》，列为上品，曰其：“久服可以轻身、延年益寿而无害。”同时益气健脾，与君药肉苁蓉配伍，加强补益后天之本，培护先天之精的作用，兼以活血通络，针对痰瘀等病理产物阻滞络脉，发挥络脉通畅精气血上濡脑髓，精神充沛记忆恢复的作用。Ministerial drug: Acanthopanax, pungent, slightly bitter, warm, enters spleen, kidney, heart channel. Tonify the kidney, invigorate the spleen, replenish qi and nourish the mind, found in "Shen Nong's Materia Medica", listed as the top grade, it is said: "long-term use can lighten the body, prolong life without harm." In essence, it has the function of cultivating and protecting the innate essence, and it also promotes blood circulation and dredging collaterals. It aims at blocking the collaterals by pathological products such as phlegm and blood stasis, and exerts the functions of smoothing the collaterals, nourishing the brain, energizing and restoring memory.
佐药：益智仁，辛，温，入脾，肾经。补肾固精，行阳退阴补肾精不足，暖肾固精，藏纳归源，对于肾精不足所致智能减退，遇事多忘，懈惰思卧者均有显效，与君药合用加强填精益髓，养精固肾的功效。Adjuvant medicine: Yizhiren, pungent, warm, enter the spleen, kidney meridian. Tonify the kidney and solidify the essence, promote yang and recede yin, nourish the deficiency of kidney essence, warm the kidney and consolidate essence, store and return to the source, and have obvious effects on mental decline caused by deficiency of kidney essence, forgetful things, laziness and sleepiness. The effect of filling essence and marrow, nourishing essence and strengthening kidney.
使药：当归，性温，味甘辛，归心、肝、脾经，补血和血，润燥滑肠，擅入血分，作为使药，引诸药入络，当归既能补血，又能活血，既可通经，又能活络，补中有动，行中有补，为血中之要药，与刺五加配合加强活血通络作用，引诸药入血，活血以通络，对年老体弱患者改善其健忘不寐症状疗效较佳。Medication: Angelica, warm in nature, sweet and pungent, Guixin, liver, spleen meridian, nourishes blood and blood, moistens dryness and smoothes intestines, enters the blood without authorization, as an envoy, introduces various medicines into the collaterals, Angelica can not only nourish blood, but also activate blood , not only can stimulate the meridian, but also activate the collaterals, tonify the movement, and tonic, it is an important medicine in the blood, cooperate with Acanthopanax to strengthen the effect of promoting blood circulation and dredging collaterals, leading various medicines into the blood, promoting blood circulation to dredge collaterals, to Elderly and infirm patients have a better effect on improving their symptoms of forgetfulness and insomnia.
综上所述，本发明药物组合物是针对老年性痴呆肾精亏虚这一基本病机变化，治疗上注重填补肾精，通络益智，方药组成中既选用了补肾填精的肉苁蓉、刺五加先后天并补，同时佐以益智仁滋填肾精，选用当归与刺五加配伍活血通络，组方药简效宏，不仅有助于改善肾精亏虚所致智力减退、遇事多忘等痴呆表现，同时可显著改善老年性痴呆患者头晕耳鸣，齿摇发脱，腰酸腿软，步行艰难，懈惰思卧等肾精亏虚所致全身性临床症状表现，提高生活质量。In summary, the pharmaceutical composition of the present invention is aimed at the basic pathogenesis change of senile dementia kidney essence deficiency, and pays attention to replenishing kidney essence in treatment, dredging collaterals and improving intelligence. Acanthopanax senticosus is supplemented with the prenatal and postnatal days, and at the same time, it is supplemented with Yizhi Renzi to nourish the kidney essence. The combination of Angelica and Acanthopanax senticosus is used to promote blood circulation and dredge collaterals. Forgetfulness and other dementia manifestations can also significantly improve the general clinical symptoms of senile dementia patients caused by kidney essence deficiency such as dizziness, tinnitus, tooth shaking and hair loss, backache and leg weakness, difficulty walking, laziness and sleepiness, etc., and improve the quality of life.
该组合物由以下重量份的中药材组成：The composition consists of the following Chinese medicinal materials in parts by weight:
肉苁蓉200-600份，刺五加400-1200份，益智仁200-600份，当归200-600份。Cistanche 200-600 parts, Acanthopanax 400-1200 parts, Yizhiren 200-600 parts, Angelica 200-600 parts.
该组合物优选由如下重量份的原料药制成：The composition is preferably made of the following raw materials in parts by weight:
肉苁蓉300-500份，刺五加600-1000份，益智仁300-500份，当归300-500份。Cistanche 300-500 parts, Acanthopanax 600-1000 parts, Yizhiren 300-500 parts, Angelica 300-500 parts.
该组合物优选由如下重量份的原料药制成：The composition is preferably made of the following raw materials in parts by weight:
肉苁蓉400份，刺五加800份，益智仁400份，当归400份。Cistanche 400 parts, Acanthopanax 800 parts, Yizhiren 400 parts, Angelica 400 parts.
该组合物优选由如下重量份的原料药制成：The composition is preferably made of the following raw materials in parts by weight:
肉苁蓉380份，刺五加700份，益智仁400份，当归500份。Cistanche 380 parts, Acanthopanax 700 parts, Yizhiren 400 parts, Angelica 500 parts.
该组合物优选由如下重量份的原料药制成：The composition is preferably made of the following raw materials in parts by weight:
肉苁蓉600份，刺五加400份，益智仁500份，当归500份。Cistanche 600 parts, Acanthopanax 400 parts, Yizhiren 500 parts, Angelica 500 parts.
本发明药物组合物，其活性组分制备包括以下步骤：The pharmaceutical composition of the present invention, its active component preparation comprises the following steps:
(1)原料处理：取益智仁破碎；(1) Raw material processing: take Yizhi kernels and crush them;
(2)称量：按配方比例称取肉苁蓉，刺五加、益智仁、当归备用；(2) Weighing: take Cistanche deserticola, Acanthopanax senticosus, Yizhiren, Angelica sinensis for subsequent use according to the proportion of the formula;
(3)取肉苁蓉、刺五加，用50％-80％乙醇回流提取2-3次，每次1-3小时，每次加8-10倍量，提取液滤过，滤液减压浓缩至相对密度为1.05～1.10(60℃)的清膏，备用；(3) Get Cistanche deserticola and Acanthopanax, reflux extraction with 50%-80% ethanol for 2-3 times, each time for 1-3 hours, add 8-10 times the amount each time, filter the extract, and concentrate the filtrate under reduced pressure to Clear paste with a relative density of 1.05-1.10 (60°C), set aside;
(4)取益智仁、当归，加8-12倍量的水，加热蒸馏6-10小时，收集挥发油；水煎液备用；药渣加8-12倍量的水，煎煮二次，每次1.5小时，两次煎液与蒸馏后的水煎液合并，减压浓缩至相对密度为1.05～1.10的清膏，与步骤(3)所得清膏合并，继续减压浓缩至相对密度为1.20-1.30的稠浸膏；(4) Take Yizhi Ren and Angelica, add 8-12 times the amount of water, heat and distill for 6-10 hours, and collect the volatile oil; decoct the liquid for later use; add 8-12 times the amount of water to the dregs, decoct twice, Each time for 1.5 hours, the two decoctions were combined with the distilled water decoction, concentrated under reduced pressure to a clear paste with a relative density of 1.05 to 1.10, combined with the clear paste obtained in step (3), and continued to be concentrated under reduced pressure until the relative density was 1.20-1.30 thick extract;
(5)取步骤(4)所得稠浸膏干燥，粉碎，所得干膏粉与挥发油共同构成本发明药物组 合物的活性组分。(5) get step (4) gained thick extract and dry, pulverize, gained dry paste powder and volatile oil constitute the active component of pharmaceutical composition of the present invention jointly.
该组合物中所述的肉苁蓉为管花肉苁蓉。The Cistanche described in the composition is Cistanche tubulosa.
该药物组合物组合物可制备成的制剂剂型为胶囊剂、片剂、丸剂、散剂或膏剂。The dosage form that the pharmaceutical composition can be prepared into is capsule, tablet, pill, powder or ointment.
所述片剂制备方法为：Described tablet preparation method is:
(1)原料处理：取益智仁破碎；(1) Raw material processing: take Yizhi kernels and crush them;
(2)称量：按配方比例称取肉苁蓉，刺五加、益智仁、当归备用；(2) Weighing: take Cistanche deserticola, Acanthopanax senticosus, Yizhiren, Angelica sinensis for subsequent use according to the proportion of the formula;
(3)取肉苁蓉、刺五加，用50％-80％乙醇回流提取2-3次，每次1-3小时，每次加8-10倍量，提取液滤过，滤液减压浓缩至相对密度为1.05～1.10(60℃)的清膏，备用；(3) Get Cistanche deserticola and Acanthopanax, reflux extraction with 50%-80% ethanol for 2-3 times, each time for 1-3 hours, add 8-10 times the amount each time, filter the extract, and concentrate the filtrate under reduced pressure to Clear paste with a relative density of 1.05-1.10 (60°C), set aside;
(4)取益智仁、当归，加8-12倍量的水，加热蒸馏6-10小时，收集挥发油；水煎液备用；药渣加8-12倍量的水，煎煮二次，每次1.5小时，两次煎液与蒸馏后的水煎液合并，减压浓缩至相对密度为1.05～1.10的清膏，与步骤(3)所得清膏合并，继续减压浓缩至相对密度为1.20-1.30的稠浸膏；干燥，粉碎，得干膏粉；(4) Take Yizhi Ren and Angelica, add 8-12 times the amount of water, heat and distill for 6-10 hours, and collect the volatile oil; decoct the liquid for later use; add 8-12 times the amount of water to the dregs, decoct twice, Each time for 1.5 hours, the two decoctions were combined with the distilled water decoction, concentrated under reduced pressure to a clear paste with a relative density of 1.05 to 1.10, combined with the clear paste obtained in step (3), and continued to be concentrated under reduced pressure until the relative density was 1.20-1.30 thick extract; dried and crushed to obtain dry paste powder;
(5)挥发油进行包合后，干燥，粉碎成细粉；(5) After the volatile oil is clathrated, it is dried and pulverized into fine powder;
(6)将步骤(4)的干膏粉与步骤(5)的细粉混合，加入辅料，制备成片剂即得。(6) Mix the dry cream powder in step (4) with the fine powder in step (5), add auxiliary materials, and prepare it into tablets.
本发明还提供了该组合物在改善记忆障碍药物中的应用。The invention also provides the application of the composition in improving memory impairment medicine.
本发明还提供了该组合物在改善胆碱能系统功能、减轻氧化应激损伤、减少神经细胞凋亡或抑制炎症反应药物中的应用。The present invention also provides the application of the composition in improving cholinergic system function, alleviating oxidative stress damage, reducing nerve cell apoptosis or inhibiting inflammatory response.
本发明组合物中，作为活性组分的原料药的拉丁名及其加工方法来自《中药大辞典》(1977年7月，第一版，上海科学技术出版社)和《中国药典》(2005年版，化学工业出版社)。In the composition of the present invention, the Latin name and the processing method thereof of the bulk drug as the active component are from "Chinese Medicine Encyclopedia" (July, 1977, first edition, Shanghai Science and Technology Press) and "Chinese Pharmacopoeia" (2005 edition) , Chemical Industry Press).
本发明药物组合物可以按常规的制剂工艺，例如，范碧亭《中药药剂学》(上海科学出版社1997年12月第1版)记载的制备工艺，制成药剂学可接受的任意常规剂型，例如胶囊剂、片剂、丸剂、散剂、软胶囊剂或膏剂等。The pharmaceutical composition of the present invention can be made into any pharmaceutically acceptable conventional dosage form according to the conventional preparation process, for example, the preparation process recorded in Fan Biting's "Chinese Medicine Pharmacy" (Shanghai Science Press, December 1997, 1st edition), such as Capsules, tablets, pills, powders, soft capsules or ointments, etc.
本发明的应用中，所述药物组合物为胶囊剂、片剂、丸剂、散剂、软胶囊剂或膏剂制剂中的一种，为使上述剂型能够实现，需在制备这些剂型时加入药学可接受的辅料，例如：填充剂、崩解剂、润滑剂、助悬剂、粘合剂、甜味剂、矫味剂、防腐剂、基质等。填充剂包括：淀粉、预胶化淀粉、乳糖、甘露醇、甲壳素、微晶纤维素、蔗糖等；崩解剂包括：淀粉、预胶化淀粉、微晶纤维素、羧甲基淀粉钠、交联聚乙烯吡咯烷酮、低取代羟丙纤维素、交联羧甲基纤维素钠等；润滑剂包括：硬脂酸镁、十二烷基硫酸钠、滑石粉、二氧化硅等；助悬剂包括：聚乙烯吡咯烷酮、微晶纤维素、蔗糖、琼脂、羟丙基甲基纤维素等；粘合剂包括，淀粉浆、聚乙烯吡咯烷酮、羟丙基甲基纤维素等；甜味剂包括：糖精钠、阿斯帕坦、蔗糖、甜 蜜素、甘草次酸等；矫味剂包括：甜味剂及各种香精；防腐剂包括：尼泊金类、苯甲酸、苯甲酸钠、山梨酸及其盐类、苯扎溴铵、醋酸氯乙定、桉叶油等；基质包括：PEG6000，PEG4000，虫蜡等。为使上述剂型能够实现中药药剂学，需在制备这些剂型时加入药学可接受的其它辅料(范碧亭《中药药剂学》，上海科学出版社1997年12月第1版中各剂型记载的辅料)。In the application of the present invention, the pharmaceutical composition is one of capsules, tablets, pills, powders, soft capsules or ointment preparations. In order to realize the above dosage forms, it is necessary to add pharmaceutically acceptable ingredients when preparing these dosage forms. Excipients, such as fillers, disintegrants, lubricants, suspending agents, binders, sweeteners, flavoring agents, preservatives, bases, etc. Fillers include: starch, pregelatinized starch, lactose, mannitol, chitin, microcrystalline cellulose, sucrose, etc.; disintegrants include: starch, pregelatinized starch, microcrystalline cellulose, sodium carboxymethyl starch, Cross-linked polyvinylpyrrolidone, low-substituted hydroxypropyl cellulose, croscarmellose sodium, etc.; lubricants include: magnesium stearate, sodium lauryl sulfate, talc, silicon dioxide, etc.; suspending agent Including: polyvinylpyrrolidone, microcrystalline cellulose, sucrose, agar, hydroxypropylmethylcellulose, etc.; binders include starch slurry, polyvinylpyrrolidone, hydroxypropylmethylcellulose, etc.; sweeteners include: Sodium saccharin, aspartame, sucrose, cyclamate, glycyrrhetinic acid, etc.; flavoring agents include: sweeteners and various essences; preservatives include: paraben, benzoic acid, sodium benzoate, sorbic acid and other Salts, benzalkonium bromide, chlorhexidine acetate, eucalyptus oil, etc.; substrates include: PEG6000, PEG4000, insect wax, etc. In order to enable the above-mentioned dosage forms to realize Chinese medicine pharmacy, it is necessary to add other pharmaceutically acceptable adjuvants when preparing these dosage forms (Fan Biting "Chinese medicine pharmacy", the adjuvant recorded in each dosage form in the first edition of Shanghai Science Publishing House in December, 1997).
针对老年性痴呆肾精亏虚这一基本病机变化，治疗上注重填补肾精，通络益智，方药组成中既选用了补肾填精的肉苁蓉、刺五加先后天并补，同时佐以益智仁滋填肾精，选用当归与刺五加配伍活血通络，组方药简效宏，不仅有助于改善肾精亏虚所致智力减退、遇事多忘等痴呆表现，同时可显著改善老年性痴呆患者头晕耳鸣，齿摇发脱，腰酸腿软，步行艰难，懈惰思卧等肾精亏虚所致全身性临床症状表现，提高生活质量。In view of the basic pathogenesis change of senile dementia, kidney essence deficiency, the treatment focuses on replenishing kidney essence, dredging collaterals and improving intelligence. In the composition of the prescription, Cistanche deserticola, Acanthopanax senticosus and Acanthopanax combined with prenatal and postnatal supplements for nourishing kidney and essence are selected, and at the same time, it is supplemented with Yizhi Renzi nourishes the kidney essence, uses Angelica and Acanthopanax to promote blood circulation and dredge collaterals, the prescription is simple and effective, not only helps to improve dementia symptoms such as mental decline and forgetfulness caused by kidney essence deficiency, but also can significantly improve the elderly Patients with dementia can experience systemic clinical symptoms caused by kidney essence deficiency, such as dizziness and tinnitus, teeth shaking and hair loss, waist soreness and leg weakness, difficulty walking, laziness and lying down, etc., and improve the quality of life.
为证实本发明组合物治疗老年性痴呆的作用，用按实施例1、实施例2方法制得的制剂(以下称RJYZ1，RJYZ2)进行了下列药理学试验。In order to confirm the effect of the composition of the present invention in treating senile dementia, the following pharmacological tests were carried out with the preparations (hereinafter referred to as RJYZ1 and RJYZ2) prepared by the methods of Example 1 and Example 2.
试验1：Test 1:
本发明药物组合物对Aβ
42寡聚体致阿尔兹海默病大鼠的影响
Effect of the pharmaceutical composition of the present invention on Alzheimer's disease rats induced by Aβ42 oligomers
摘要Summary
【目的】采用大鼠双侧海马CA1区注射Aβ
42寡聚体致AD模型，评价本发明药物组合物对AD大鼠学习、记忆能力的改善作用。【方法】120只动物按体重随机分为空白组、假手术组、模型组、石杉碱甲组、抗脑衰组、本发明药物组合物组1，本发明药物组合物组2，对照药组，雌雄各半，本发明药物组合物组1，本发明药物组合物组2剂量为3.2生药/kg×day
-1，相当于临床人用剂量的8倍，双侧海马CA1区注射Aβ
42寡聚体造模，造模1w后动物按体重灌胃给药，3w后进行水迷宫测试，5w后取双侧海马，生化检测海马ACHE、SOD、MDA及血清SOD、MDA，免疫印迹检测Aβ、Tau、p-Tau、Bcl-2、Bax、Caspase-3、IL-6、IL-1β、IL-18、TNF-α。【结果】1.水迷宫实验结果，与模型组比较，本发明药物组合物组1，本发明药物组合物组2，对照药组定位航行实验潜伏期、总路程明显减少(P<0.01)，空间探索实验站台穿越次数、站台所在象限时间明显增加(P<0.01或P<0.05)。2.胆碱能系统指标结果，本发明药物组合物组1，本发明药物组合物组2，对照药组海马ACHE活力较模型组明显减少(P<0.01或P<0.05)。3.氧化应激指标结果，本发明药物组合物组1，本发明药物组合物组2，对照药组海马MDA含量较模型组虽无明显差异(P>0.05)，但呈减少趋势。4.本发明药物组合物组1，本发明药物组合物组2，对照药组Aβ表达较模型组明显减少(P<0.01)。5.本发明药物组合物组1，本发明药物组合物组2，对照药组p-Tau表达较模型组明显减少(P<0.01或P<0.05)。6.凋亡指标结果，本发明药物组合物组1，本发明药物组 合物组2，对照药组Caspase-3表达较模型组明显减少(P<0.01)；本发明药物组合物组1，本发明药物组合物组2Bcl-2/Bax比例较模型组明显增加(P<0.01或P<0.05)。7.炎症指标结果，本发明药物组合物组1，本发明药物组合物组2，对照药组IL-6、IL-1β、IL-18、TNF-α表达较模型组明显减少(P<0.01或P<0.05)。【结论】本发明药物组合物组1，本发明药物组合物组2，对照药组对Aβ
42寡聚体致AD大鼠学习、记忆能力有明显改善作用，其作用可能与改善胆碱能系统功能、减轻氧化应激损伤、减少神经细胞凋亡、抑制炎症反应有关。
[Objective] The AD model was induced by injecting Aβ42 oligomers in the CA1 region of the bilateral hippocampus of rats, and the improvement effect of the pharmaceutical composition of the present invention on the learning and memory abilities of AD rats was evaluated. [Method] 120 animals were randomly divided into blank group, sham operation group, model group, huperzine A group, anti-brain failure group, pharmaceutical composition group 1 of the present invention, pharmaceutical composition group 2 of the present invention, control drug The dosage of the pharmaceutical composition group 1 of the present invention and the pharmaceutical composition group 2 of the present invention are 3.2 crude drugs/kg×day -1 , which is equivalent to 8 times the clinical human dose, and Aβ 42 is injected into the CA1 region of the bilateral hippocampus. Oligomer modeling, 1 week after modeling, animals were administered orally according to body weight, water maze test was performed after 3 weeks, bilateral hippocampus was taken after 5 weeks, hippocampal ACHE, SOD, MDA and serum SOD, MDA were detected biochemically, and Aβ was detected by Western blot , Tau, p-Tau, Bcl-2, Bax, Caspase-3, IL-6, IL-1β, IL-18, TNF-α. [Result] 1. water maze test results, compared with the model group, the pharmaceutical composition group 1 of the present invention, the pharmaceutical composition group 2 of the present invention, the latent period of the positioning navigation experiment of the control group, the total distance significantly reduced (P<0.01), the space The times of platform crossing and the quadrant time of the platform in the exploration experiment increased significantly (P<0.01 or P<0.05). 2. The results of the cholinergic system index, the pharmaceutical composition group 1 of the present invention, the pharmaceutical composition group 2 of the present invention, and the ACHE activity of the hippocampus in the control group were significantly reduced compared with the model group (P<0.01 or P<0.05). 3. Oxidative stress index results, although the pharmaceutical composition group 1 of the present invention, the pharmaceutical composition group 2 of the present invention, and the hippocampus MDA content of the control group have no significant difference compared with the model group (P>0.05), they show a decreasing trend. 4. The expression of Aβ in the pharmaceutical composition group 1 of the present invention, the pharmaceutical composition group 2 of the present invention, and the control drug group was significantly lower than that of the model group (P<0.01). 5. The expression of p-Tau in the pharmaceutical composition group 1 of the present invention, the pharmaceutical composition group 2 of the present invention, and the control drug group was significantly lower than that of the model group (P<0.01 or P<0.05). 6. Apoptosis index result, pharmaceutical composition group 1 of the present invention, pharmaceutical composition group 2 of the present invention, contrast drug group Caspase-3 expression significantly reduces (P<0.01) than model group; Pharmaceutical composition group 1 of the present invention, this invention The ratio of 2Bcl-2/Bax in the inventive pharmaceutical composition group was significantly higher than that in the model group (P<0.01 or P<0.05). 7. Inflammation index results, the pharmaceutical composition group 1 of the present invention, the pharmaceutical composition group 2 of the present invention, and the expression of IL-6, IL-1β, IL-18, TNF-α in the control group were significantly reduced compared with the model group (P<0.01 or P<0.05). [Conclusion] The pharmaceutical composition group 1 of the present invention, the pharmaceutical composition group 2 of the present invention, and the control drug group have obvious improvement effects on the learning and memory abilities of AD rats induced by Aβ42 oligomers, and their effects may be related to improving the cholinergic system. function, reducing oxidative stress damage, reducing nerve cell apoptosis, and inhibiting inflammatory response.
缩略词表Acronym list
AD Alzheimer's disease 阿尔兹海默病AD Alzheimer's disease Alzheimer's disease
Aβ β-amyloidprotein β-淀粉样蛋白Aβ β-amyloidprotein β-amyloid protein
ACHE Acetlcholinesterase 乙酰胆碱酯酶ACHE Acetlcholinesterase Acetylcholinesterase
MDA malondialdehyde 丙二醛MDA malondiaaldehyde
SOD superoxide dismutase 超氧化物歧化酶SOD superoxide dismutase superoxide dismutase
p-Tau phosphorylation-Tau 磷酸化微管相关蛋白p-Tau phosphorylation-Tau phosphorylates microtubule-associated protein
Bcl-2 B cell lymphoma/lewkmia-2 B细胞淋巴瘤/白血病-2Bcl-2 B cell lymphoma/lewkmia-2 B cell lymphoma/leukemia-2
Bax Bcl-2 Assaciated X protein B细胞淋巴瘤/白血病-相关X蛋白Bax Bcl-2 Associated X protein B-cell lymphoma/leukemia-associated X protein
Caspase-3 cysteinyl aspartate-specific proteinase 半胱氨酸天冬氨酸蛋白酶-3Caspase-3 cysteinyl aspartate-specific proteinase Caspase-3
IL-6 interleukin-6 白介素-6IL-6 interleukin-6 interleukin-6
IL-1β interleukin-1β 白介素-1βIL-1β interleukin-1β Interleukin-1β
IL-18 interleukin-18 白介素-18IL-18 interleukin-18 interleukin-18
TNF-α tumor necrosis factor-α 肿瘤坏死因子-αTNF-α tumor necrosis factor-α tumor necrosis factor-α
APP β-amyloidprecursorprotein β-淀粉样前体蛋白APP β-amyloidprecursorprotein β-amyloid precursor protein
Ach acetylcholine 乙酰胆碱Ach acetylcholine
实验目的Purpose
采用大鼠双侧海马CA1区注射Aβ
42寡聚体致AD模型，评价本发明药物组合物对AD大鼠学习、记忆能力的改善作用。
The AD model is induced by injecting Aβ42 oligomers into the CA1 region of the bilateral hippocampus of rats, and the improvement effect of the pharmaceutical composition of the present invention on the learning and memory abilities of AD rats is evaluated.
1实验材料1 Experimental materials
1.1供试品1.1 Test product
1.1.1名称：本发明药物组合物1，缩写：RJYZ1，本发明药物组合物2，缩写：RJYZ2，对照药药物，按照CN111939237A专利实施例1制备的胶囊剂内容物。1.1.1 Name: Pharmaceutical composition 1 of the present invention, abbreviation: RJYZ1, pharmaceutical composition 2 of the present invention, abbreviation: RJYZ2, control drug, the contents of capsules prepared according to Example 1 of CN111939237A patent.
1.1.2性状：棕色粉末。1.1.2 Properties: brown powder.
1.1.3拟临床适应症：补肾填精、通络益智。老年性痴呆症。1.1.3 Proposed clinical indications: tonifying kidney and replenishing essence, dredging collaterals and improving intelligence. Alzheimer's disease.
1.1.4拟临床用量：口服，拟临床人用量为24.0g生药/天。1.1.4 Proposed clinical dosage: oral administration, the proposed clinical human dosage is 24.0g crude drug/day.
1.1.5含量及规格：5.0g生药/g干膏粉。1.1.5 Content and specification: 5.0g crude drug/g dry cream powder.
1.1.6来源和批号：来源：河北以岭医院，批号：20150406。1.1.6 Source and batch number: Source: Hebei Yiling Hospital, batch number: 20150406.
1.1.7保存条件：密封。1.1.7 Storage conditions: sealed.
1.2阳性药、工具药及主要试剂1.2 Positive drugs, tool drugs and main reagents
Aβ
42寡聚体：北京交通大学理学院生物科学与技术研究所合成提供。
Aβ42 oligomer: provided by the Institute of Biological Science and Technology, School of Science, Beijing Jiaotong University.
石杉碱甲片：河南太龙药业股份有限公司，批号：140902。Huperzine A Tablets: Henan Tailong Pharmaceutical Co., Ltd., batch number: 140902.
抗脑衰胶囊：石家庄四药有限公司，批号：KN15031001。Anti-brain failure capsule: Shijiazhuang No.4 Medicine Co., Ltd., batch number: KN15031001.
10％福尔马林缓冲液：北京益利精细化学品有限公司，批号：20150504。10% buffered formalin: Beijing Yili Fine Chemicals Co., Ltd., batch number: 20150504.
SOD检测试剂盒：南京建成生物工程研究所，批号：20150821。SOD detection kit: Nanjing Jiancheng Institute of Bioengineering, batch number: 20150821.
MDA检测试剂盒：南京建成生物工程研究所，批号：20150826。MDA detection kit: Nanjing Jiancheng Institute of Bioengineering, batch number: 20150826.
ACHE检测试剂盒：南京建成生物工程研究所，批号：20150820。ACHE detection kit: Nanjing Jiancheng Institute of Bioengineering, batch number: 20150820.
BCA蛋白定量试剂盒：北京索莱宝科技有限公司，批号：20151015。BCA protein quantification kit: Beijing Suo Laibao Technology Co., Ltd., batch number: 20151015.
Aβ一抗：abcam，批号：ab39377。Aβ primary antibody: abcam, batch number: ab39377.
Tau一抗：abcam，批号：ab32057。Tau primary antibody: abcam, batch number: ab32057.
p-Tau一抗：abcam，批号：ab131354。p-Tau primary antibody: abcam, lot number: ab131354.
Bcl-2一抗：abcam，批号：ab7973。Bcl-2 primary antibody: abcam, lot number: ab7973.
Bax一抗：abcam，批号：ab7977。Bax primary antibody: abcam, lot number: ab7977.
Caspase-3一抗：abcam，批号：ab44976。Caspase-3 primary antibody: abcam, lot number: ab44976.
IL-6一抗：abcam，批号：ab83339。IL-6 primary antibody: abcam, batch number: ab83339.
IL-1β一抗：abcam，批号：ab9722。IL-1β primary antibody: abcam, batch number: ab9722.
IL-18一抗：abcam，批号：ab191860。IL-18 primary antibody: abcam, batch number: ab191860.
TNF-α一抗：abcam，批号：ab6671。TNF-α primary antibody: abcam, batch number: ab6671.
1.3实验系统1.3 Experimental system
1.3.1动物种系：SD大鼠。1.3.1 Animal species: SD rats.
1.3.2动物级别：SPF级。1.3.2 Animal grade: SPF grade.
1.3.3动物性别和数量：雌雄各半，共120只。1.3.3 Sex and number of animals: half male and half male, 120 animals in total.
1.3.4动物年龄：7周龄。1.3.4 Animal age: 7 weeks old.
1.3.5动物体重：180-210g。1.3.5 Animal weight: 180-210g.
1.3.6动物来源：购于北京维通利华实验动物技术有限公司，合格证号：11400700105927，许可证号：SCXK(京)2012-0001，接收日期2015年7月22日。1.3.6 Animal source: purchased from Beijing Weitong Lihua Experimental Animal Technology Co., Ltd., certificate number: 11400700105927, license number: SCXK (Beijing) 2012-0001, and the date of receipt was July 22, 2015.
1.3.7饲养条件：动物饲养于河北省中西医结合医药研究院新药评价中心。大鼠笼养，光照12小时/天，温度20～26℃，相对湿度40～70％。1.3.7 Raising conditions: Animals were raised in the New Drug Evaluation Center of Hebei Academy of Integrated Traditional Chinese and Western Medicine. Rats were housed in a cage with 12 hours of light per day, a temperature of 20-26°C, and a relative humidity of 40-70%.
1.3.8检疫过程：新动物检疫期5天，检疫期间动物饮水和摄食正常，健康状况良好，无疾病和死亡征兆。1.3.8 Quarantine process: The quarantine period for new animals is 5 days. During the quarantine period, the animals drink water and eat normally, are in good health, and have no signs of disease or death.
1.3.9饲料：实验级颗粒鼠粮，江苏省协同医药生物工程有限责任公司提供，生产许可证：苏饲审(2014)01008。1.3.9 Feed: experimental-grade granular mouse food, provided by Jiangsu Synergy Pharmaceutical Bioengineering Co., Ltd., production license: Su Wei Shen (2014) 01008.
1.3.10饮水：灌装普通用水供动物自由饮用，每日冲洗饮水瓶并换水一次。1.3.10 Drinking water: fill with ordinary water for animals to drink freely, rinse the drinking water bottle and change the water once a day.
1.3.11垫料：实验动物普通级垫料，由河北省实验动物中心提供，生产许可证：SCXK(冀)2013-2-001。1.3.11 Bedding: Common grade bedding for experimental animals, provided by Hebei Experimental Animal Center, production license: SCXK (Ji) 2013-2-001.
1.3.12标识：5％苦味酸标记。1.3.12 Label: 5% picric acid label.
2实验方法2 Experimental methods
2.1实验设计依据2.1 Experimental Design Basis
2.1.1采用标准：中华人民共和国卫生部药政管理局颁布的中药新药研究指南(药学，药理学，毒理学)、新药(西药)临床前研究指导原则汇编(药学，药理学，毒理学)，人民卫生出版社出版的《中药药理研究方法学》、《药理实验方法学》及相关文献资料确定。2.1.1 Standards used: Guidelines for New Drug Research of Traditional Chinese Medicine (Pharmacy, Pharmacology, Toxicology) and Guidelines for Preclinical Research of New Drugs (Western Medicine) issued by the Drug Administration of the Ministry of Health of the People's Republic of China (Pharmacy, Pharmacology, Toxicology) , "Chinese Medicine Pharmacological Research Methodology" and "Pharmacological Experimental Methodology" published by People's Health Publishing House and related literature.
2.1.2委托单位提供资料：RJYZ1、RJYZ2、对照药组拟临床人用量为24.0g生药/天，人按60kg体重计算，则拟临床使用剂量为0.4g生药/kg，供试品干膏粉含量为5.0g生药/g干膏粉，批号20150406。2.1.2 Information provided by entrusting unit: RJYZ1, RJYZ2, and control drug group are intended to use 24.0 g of crude drug per day, and calculated based on a body weight of 60 kg, the proposed clinical dose is 0.4 g of crude drug/kg. The content is 5.0g crude drug/g dry cream powder, batch number 20150406.
2.2剂量与分组2.2 Dosage and grouping
大鼠按体重随机分为8组，即空白组，假手术组，模型组，石杉碱甲组，抗脑衰组，RJYZ1组、RJYZ2组、对照药组，雌雄各半，拟定为3.2g生药/kg×day
-1，相当于临床人用剂量的8倍，石杉碱甲临床最大日用量(9片)为450μg/人，抗脑衰胶囊临床最大日用量(18粒)为32.02g生药/人，大鼠给药剂量为临床最大日用量的8倍，分别为60μg/kg×day
-1及4.3g生药/kg×day
-1。见表1。
Rats were randomly divided into 8 groups according to body weight, namely, blank group, sham operation group, model group, huperzine A group, anti-brain failure group, RJYZ1 group, RJYZ2 group, and control drug group. Crude drug/kg×day -1 , equivalent to 8 times the clinical human dose, the maximum clinical daily dose of huperzine A (9 tablets) is 450μg/person, and the maximum clinical daily dose of anti-brain failure capsules (18 capsules) is 32.02g Crude drug/human, rat administration dose is 8 times the clinical maximum daily dose, respectively 60μg/kg×day -1 and 4.3g crude drug/kg×day -1 . See Table 1.
表1 RJYZ对Aβ
42寡聚体致阿尔兹海默病大鼠的影响分组及给药剂量对照表
Table 1 Effect of RJYZ on Aβ42 oligomer-induced Alzheimer's disease rats grouping and dosage comparison table
2.3给药方法2.3 Administration method
灌胃给药，与临床推荐的口服途径相一致。Oral administration is consistent with the clinically recommended oral route.
2.4供试品配制和保存2.4 Preparation and storage of the test product
受试药用蒸馏水配制成实验用浓度(见表1)，配制后置2～8℃保存备用，阳性药现用现配。The test drug was prepared with distilled water to the concentration used in the experiment (see Table 1). After preparation, it was stored at 2-8°C for future use. The positive drug was prepared immediately after use.
2.5供试品的给予2.5 Administration of the test article
动物按10ml/kg灌胃给药，空白、假手术及模型组给予蒸馏水，每日给药1次，连续5w。Animals were given intragastric administration of 10ml/kg, and distilled water was given to the blank, sham-operated and model groups, once a day for 5 consecutive weeks.
2.6步骤、方法及检测指标2.6 Steps, methods and detection indicators
2.6.1步骤：新接收动物标号，检疫5d，检疫完成后按体重随机选出空白组12只动物，假手术组14只动物，雌雄各半，剩余动物双侧海马CA1区注射1μg/μl Aβ
42寡聚体5μl，假手术组注射等量生理盐水，空白组不作处理，手术结束1w后将剩余动物按体重分组，即模型组、石杉碱甲组、抗脑衰组、RJYZ低、中、高剂组，每组14只，分组完成后开始灌胃给药，空白、假手术及模型组给予蒸馏水，连续5w，每周记录一次体重，给药3w后，进行学习记忆能力测试即水迷宫行为学试验，行为学结束后每组任意取3只动物，灌流固定取脑备用，给药结束后剩余动物10％水合氯醛麻醉，腹主动脉采血，3000rpm离心10min，取血清，备血生化检测，冰上取双侧海马，液氮保存，3只动物备免疫印迹检测，其余匀浆备组织生化检测。
2.6.1 Steps: Newly received animal labels, quarantined for 5 days, randomly selected 12 animals in the blank group and 14 animals in the sham operation group, half male and half male, and injected 1 μg/μl Aβ in the bilateral hippocampus CA1 area of the remaining animals 42 oligomers 5 μl, the sham operation group was injected with the same amount of normal saline, the blank group was not treated, and the remaining animals were divided into groups according to body weight 1 week after the operation, namely the model group, huperzine A group, anti-brain failure group, RJYZ low, medium , high-dose group, 14 rats in each group, after the completion of grouping, intragastric administration began, blank, sham operation and model groups were given distilled water, continuous 5w, body weight was recorded once a week, after administration for 3w, the learning and memory ability test was carried out. Maze behavior test, after the end of the behavior study, randomly select 3 animals in each group, fix the brain by perfusion, and take the brain for later use. After the administration, the remaining animals were anesthetized with 10% chloral hydrate, blood was collected from the abdominal aorta, centrifuged at 3000rpm for 10 minutes, serum was taken, and blood was prepared For biochemical testing, bilateral hippocampi were taken on ice and stored in liquid nitrogen. Three animals were prepared for Western blot testing, and the rest were homogenized for tissue biochemical testing.
2.6.2方法及检测指标2.6.2 Methods and detection indicators
2.6.2.1手术方法：用10％水合氯醛腹腔注射麻醉大鼠，将头部固定在立体定向仪上，剃毛消毒，在头背中部纵向切口，暴露颅骨，参照澳大利亚新南威尔士大学Paxinos教授编写的《大鼠脑立体定向图谱》以及包新民等编著的《大鼠脑立体定位图谱》，选双侧海马CA1区为注射部位，定位坐标：前囟后3.5mm，中线两侧2.1mm，硬脑膜下3.6mm，在坐标点处用牙科钻环行钻开颅骨，缓慢垂直进针至靶点，然后将5μl(1μg/μl)Aβ
42寡聚体恒速缓慢注入，注射时间5min，留针3min，再缓慢撤针3min，以保证溶液充分弥散，假手术组给 予等量生理盐水，其余操作同前，皮肤切开处给予少许青霉素粉剂，缝合切口。
2.6.2.1 Surgical method: the rat was anesthetized by intraperitoneal injection of 10% chloral hydrate, the head was fixed on the stereotaxic instrument, the hair was shaved and disinfected, and a longitudinal incision was made in the middle of the back of the head to expose the skull, referring to Professor Paxinos of the University of New South Wales, Australia The "Rat Brain Stereotaxic Atlas" compiled by Bao Xinmin et al. and the "Rat Brain Stereotaxic Atlas" compiled by Bao Xinmin et al. selected the bilateral hippocampal CA1 area as the injection site, and the positioning coordinates: 3.5mm behind the bregma, 2.1mm on both sides of the midline, 3.6 mm below the dura mater, drill the skull with a dental drill circularly at the coordinate point, slowly insert the needle vertically to the target point, then inject 5 μl (1 μg/μl) Aβ 42 oligomer at a constant speed and slowly, the injection time is 5 minutes, and the needle is retained for 3 minutes , and then slowly withdraw the needle for 3 minutes to ensure that the solution was fully diffused. The sham operation group was given the same amount of normal saline, and the rest of the operations were the same as before. A little penicillin powder was given to the skin incision and the incision was sutured.
2.6.2.2水迷宫行为学方法：水迷宫实验主要用于测试实验动物对空间位置学习记忆能力，其由圆形水池、平台和视频追踪系统组成，圆形水池被等分为4个象限，本次共涉及两个试验，包括定位航行试验(4d)，空间探索试验(1d)。2.6.2.2 Water maze behavioral method: The water maze experiment is mainly used to test the ability of experimental animals to learn and remember spatial positions. It consists of a circular pool, a platform and a video tracking system. The circular pool is divided into four quadrants. This time involved two tests, including positioning navigation test (4d) and space exploration test (1d).
定位航行试验：将平台固定于第一象限中心水下2cm，水温控制在22-26℃，在平台对侧远离平台处，任意选两个与平台等距的入水点，将动物面朝池壁轻轻放入水中，最大游泳时间设为90s，如果90s内大鼠找到平台，让其在平台上保持10s，如果未找到，则人为将其放到平台上10s，每天2次，连续3d，第4d记录各组大鼠从两入水点找到平台的平均时间(逃避潜伏期)及总路程。Positioning navigation test: fix the platform at the center of the first quadrant 2cm below the water, control the water temperature at 22-26°C, choose two water entry points at the opposite side of the platform away from the platform, and place the animals facing the pool wall Gently put it into the water, and set the maximum swimming time to 90s. If the rat finds the platform within 90s, let it stay on the platform for 10s. On the 4th day, the average time (escape latency) and the total distance of the rats in each group to find the platform from the two water entry points were recorded.
空间探索试验：定位航行试验结束后，撤除平台，然后选择任一相同入水点将大鼠放入水中，记录60s内大鼠在第一象限停留时间以及穿过原平台位置的次数。Space exploration test: After the positioning navigation test, the platform was removed, and then any same water entry point was selected to put the rat into the water, and the time the rat stayed in the first quadrant and the number of times the rat passed through the original platform position within 60 seconds was recorded.
2.6.2.3生化、免疫印迹2.6.2.3 Biochemistry, immunoblotting
大鼠麻醉，腹主动脉采血离心取血清，备血生化检测，冰上取双侧海马，液氮保存，3只动物备免疫印迹检测，其余匀浆备组织生化检测。Rats were anesthetized, abdominal aorta blood was collected and centrifuged to obtain serum, blood was prepared for biochemical testing, bilateral hippocampus was collected on ice, and stored in liquid nitrogen, 3 animals were prepared for Western blot testing, and the rest were homogenized for tissue biochemical testing.
海马组织生化检测：ACHE，SOD，MDA。Biochemical detection of hippocampal tissue: ACHE, SOD, MDA.
海马组织免疫印迹检测：Aβ，Tau，p-Tau，Bcl-2，Bax，Caspase-3，IL-6，IL-1β，IL-18，TNF-α。Western blot detection of hippocampal tissue: Aβ, Tau, p-Tau, Bcl-2, Bax, Caspase-3, IL-6, IL-1β, IL-18, TNF-α.
血生化检测：SOD，MDA。Blood biochemical tests: SOD, MDA.
2.7相关工作人员通知2.7 Relevant staff notification
购买动物时通知动物室，在动物出现异常情况时通知病理室进行处理。Notify the animal room when purchasing animals, and notify the pathology room for processing when animals appear abnormal.
2.8主要仪器系统2.8 Main instrument systems
2.9统计方法2.9 Statistical methods
实验数据采用SPSS11.5统计软件进行分析处理，统计结果用均数±标准差
表示，首先进行正态性检验，符合正态分布的数据，均数比较用单因素方差分析(One-Way ANOVA)，若方差齐，两两比较采用最小显著差法(LSD)，若方差不齐则采用Dunnett’s T3检验行两两比较；如不符合正态分布，则用非参数检验进行统计分析。
The experimental data is analyzed and processed by SPSS11.5 statistical software, and the statistical results are expressed as mean ± standard deviation It means that the normality test is carried out first, and the data conforming to the normal distribution are compared with one-way analysis of variance (One-Way ANOVA). If the variances are equal, the least significant difference method (LSD) is used for pairwise comparison. For Qi, the Dunnett's T3 test was used for pairwise comparison; if the normal distribution was not met, the non-parametric test was used for statistical analysis.
3结果3 results
3.1 RJYZ对AD大鼠学习、记忆能力的影响。3.1 The effect of RJYZ on the learning and memory abilities of AD rats.
由表2可见，与假手术组比较，模型组水迷宫定位航行实验潜伏期、总路程均明显增加(P<0.01)，RJYZ1组、RJYZ2组、对照药组较模型组均明显减少(P<0.01)；与假手术组比较，模型组空间探索实验站台穿越次数、站台所在象限时间明显减少(P<0.01)，RJYZ1组、RJYZ2组、对照药组较模型组均明显增加(P<0.01或P<0.05)。可见海马区注射Aβ
42寡聚体使动物出现了学习、记忆能力障碍，RJYZ能改善学习、记忆能力。
It can be seen from Table 2 that compared with the sham operation group, the incubation period and the total distance of the water maze navigation test in the model group were significantly increased (P<0.01), and the RJYZ1 group, RJYZ2 group, and control drug group were significantly reduced compared with the model group (P<0.01 ); compared with the sham operation group, the number of space exploration platform crossings and the quadrant time of the platform in the model group were significantly reduced (P<0.01), and the RJYZ1 group, RJYZ2 group, and control drug group were significantly increased compared with the model group (P<0.01 or P<0.01). <0.05). It can be seen that the injection of Aβ42 oligomers in the hippocampus caused the animals to have learning and memory impairments, and RJYZ can improve learning and memory abilities.
3.2 RJYZ对AD大鼠胆碱能神经系统功能的影响。3.2 Effect of RJYZ on the function of cholinergic nervous system in AD rats.
表2：RJYZ对Aβ
42寡聚体致阿尔兹海默病大鼠水迷宫学习记忆的影响
Table 2: Effect of RJYZ on water maze learning and memory in rats with Alzheimer's disease induced by Aβ42 oligomers
注：与假手术组比较：
△P＜0.05，
△△P＜0.01；与模型组比较：*P＜0.05，**P＜0.01。
Note: Compared with the sham operation group: △ P<0.05, △△ P<0.01; compared with the model group: *P<0.05, **P<0.01.
由表3可见，与假手术组比较，模型组大鼠海马ACHE活力明显增加(P<0.01)，RJYZ1组、RJYZ2组、对照药组海马ACHE活力较模型组明显减少(P<0.01或P<0.05)。可见RJYZ能够通过减少海马ACHE活力，间接增加Ach含量，改善AD大鼠胆碱能神经系统功能，提高学习、记忆能力。As can be seen from Table 3, compared with the sham operation group, the ACHE activity in the hippocampus of the rats in the model group was significantly increased (P<0.01), and the ACHE activity in the hippocampus of the RJYZ1 group, RJYZ2 group, and the control group was significantly reduced compared with the model group (P<0.01 or P<0.01). 0.05). It can be seen that RJYZ can reduce the activity of ACHE in the hippocampus and indirectly increase the content of Ach, improve the function of the cholinergic nervous system in AD rats, and improve the learning and memory abilities.
3.3 RJYZ对AD大鼠氧化应激能力的影响。3.3 The effect of RJYZ on the oxidative stress ability of AD rats.
由表3可见，与假手术组比较，模型组大鼠海马MDA含量明显增加(P<0.05)，RJYZ1组、RJYZ2组、对照组海马MDA含量较模型组虽无明显差异(P>0.05)，但呈减少趋势；海马、血清SOD活力及血清MDA含量各组间无明显差异(P>0.05)。可见RJYZ能够通过减少海马MDA含量，减轻氧化应激损伤，改善学习、记忆能力。As can be seen from Table 3, compared with the sham operation group, the MDA content in the hippocampus of the rats in the model group was significantly increased (P<0.05), although there was no significant difference in the MDA content in the hippocampus of the RJYZ1 group, the RJYZ2 group, and the control group compared with the model group (P>0.05), But it showed a decreasing trend; hippocampus, serum SOD activity and serum MDA content were not significantly different among the groups (P>0.05). It can be seen that RJYZ can reduce oxidative stress damage and improve learning and memory by reducing the content of MDA in the hippocampus.
表3：RJYZ对Aβ
42寡聚体致阿尔兹海默病大鼠生化指标的影响
Table 3: Effect of RJYZ on the biochemical indicators of Alzheimer's disease rats induced by Aβ42 oligomers
注与假手术组比较：
△P＜0.05，
△△P＜0.01；与模型组比较：*P＜0.05，**P＜0.01。
Note Compared with the sham operation group: △ P<0.05, △△ P<0.01; compared with the model group: *P<0.05, **P<0.01.
3.4 RJYZ对AD大鼠海马区Aβ表达的影响。3.4 The effect of RJYZ on the expression of Aβ in the hippocampus of AD rats.
由表4可见，与假手术组比较，模型组Aβ表达明显增加(P<0.01)，RJYZ1组、RJYZ2组、对照药组Aβ表达较模型组明显减少(P<0.01)。可见RJYZ能通过减少AD大鼠海马区Aβ沉积，改善学习、记忆能力。It can be seen from Table 4 that, compared with the sham operation group, the expression of Aβ in the model group was significantly increased (P<0.01), and the expression of Aβ in the RJYZ1 group, RJYZ2 group, and control drug group was significantly lower than that in the model group (P<0.01). It can be seen that RJYZ can improve the learning and memory ability by reducing the Aβ deposition in the hippocampus of AD rats.
3.5 RJYZ对AD大鼠海马区p-Tau表达的影响。3.5 The effect of RJYZ on the expression of p-Tau in the hippocampus of AD rats.
由表4可见，与假手术组比较，模型组p-Tau表达明显增加(P<0.01)，RJYZ1组、RJYZ2组、对照药组p-Tau表达较模型组明显减少(P<0.01或P<0.05)。可见RJYZ能通过减少AD大鼠海马区p-Tau过表达，减轻神经纤维缠结造成的神经元变性坏死，改善学习、记忆能力。As can be seen from Table 4, compared with the sham operation group, the expression of p-Tau in the model group was significantly increased (P<0.01), and the expression of p-Tau in the RJYZ1 group, RJYZ2 group, and the control group was significantly lower than that in the model group (P<0.01 or P<0.01). 0.05). It can be seen that RJYZ can reduce the overexpression of p-Tau in the hippocampus of AD rats, reduce the degeneration and necrosis of neurons caused by neurofibrillary tangles, and improve the learning and memory abilities.
3.6 RJYZ对AD大鼠海马细胞凋亡的影响。3.6 Effect of RJYZ on hippocampal cell apoptosis in AD rats.
由表4可见，与假手术组比较，模型组Caspase-3表达明显增加(P<0.01)，RJYZ1组、RJYZ2组、对照药组Caspase-3表达较模型组明显减少(P<0.01)；RJYZ1组、RJYZ2组Bcl-2/Bax比例较模型组明显增加(P<0.01或P<0.05)。可见RJYZ能通过减少AD大鼠海马区凋亡蛋白酶Caspase-3以及增加Bcl-2/Bax比例，保护细胞正常功能，改善学习、记忆能力。As can be seen from Table 4, compared with the sham operation group, the expression of Caspase-3 in the model group significantly increased (P<0.01), and the expression of Caspase-3 in the RJYZ1 group, the RJYZ2 group, and the control drug group decreased significantly compared with the model group (P<0.01); The ratio of Bcl-2/Bax in the control group and the RJYZ2 group was significantly higher than that in the model group (P<0.01 or P<0.05). It can be seen that RJYZ can protect the normal function of cells and improve the ability of learning and memory by reducing Caspase-3 and increasing the ratio of Bcl-2/Bax in the hippocampus of AD rats.
3.7 RJYZ对AD大鼠海马炎症反应的影响。3.7 Effect of RJYZ on hippocampal inflammatory response in AD rats.
由表4可见，与假手术组比较，模型组IL-6、IL-1β、IL-18、TNF-α表达明显增加(P<0.01或P<0.05)，RJYZ1组、RJYZ2组、对照药组IL-6表达较模型组明显减少(P<0.01)，RJYZ1组、RJYZ2组IL-1β、IL-18、TNF-α表达较模型组明显减少(P<0.05)。可见RJYZ能够通过减少炎症因子表达，减轻炎症反应，保护细胞正常功能，改善学习、记忆能力。As can be seen from Table 4, compared with the sham operation group, the expression of IL-6, IL-1β, IL-18, and TNF-α in the model group increased significantly (P<0.01 or P<0.05), and the RJYZ1 group, RJYZ2 group, and control drug group The expression of IL-6 was significantly lower than that of the model group (P<0.01), and the expression of IL-1β, IL-18, and TNF-α in the RJYZ1 group and RJYZ2 group was significantly lower than that of the model group (P<0.05). It can be seen that RJYZ can reduce the expression of inflammatory factors, reduce the inflammatory response, protect the normal function of cells, and improve learning and memory abilities.
4结论4 Conclusion
RJYZ对Aβ
42寡聚体致AD大鼠学习、记忆能力有明显改善作用，其作用可能是通过降低ACHE活力，改善胆碱能系统功能；减轻因海马MDA含量增多引起的氧化应激损伤；减少海马区Aβ沉积；减少海马区p-Tau过表达引起的神经纤维缠结；减少凋亡蛋白酶Caspase-3 表达，增加抗凋亡Bcl-2/Bax比例，减少神经细胞凋亡；抑制炎症因子IL-6、IL-1β、IL-18、TNF-α表达，减少炎症反应实现的。
RJYZ can significantly improve the learning and memory ability of AD rats induced by Aβ 42 oligomers, which may be through reducing the activity of ACHE and improving the function of cholinergic system; reducing the oxidative stress damage caused by the increase of MDA content in the hippocampus; reducing Aβ deposition in the hippocampus; reduce neurofibrillary tangles caused by overexpression of p-Tau in the hippocampus; reduce the expression of caspase-3, increase the ratio of anti-apoptotic Bcl-2/Bax, reduce nerve cell apoptosis; inhibit the inflammatory factor IL -6, IL-1β, IL-18, TNF-α expression, reducing inflammatory response.
表4：RJYZ对Aβ
42寡聚体致阿尔兹海默病大鼠海马组织蛋白表达的影响
Table 4: Effect of RJYZ on protein expression in hippocampus of rats with Alzheimer's disease induced by Aβ42 oligomers
注：与假手术组比较：△P＜0.05，△△P＜0.01；与模型组比较：*P＜0.05，**P＜0.01。Note: Compared with the sham operation group: △P<0.05, △△P<0.01; compared with the model group: *P<0.05, **P<0.01.
试验2：Test 2:
本发明药物组合物对乙醇致小鼠记忆再现缺失模型的影响Influence of the pharmaceutical composition of the present invention on the memory loss model of mice induced by ethanol
摘要Summary
【目的】采用乙醇致小鼠记忆再现缺失模型，观察本发明药物组合物对记忆再现缺失小鼠记忆能力的改善作用。【方法】72只ICR小鼠雌雄各半，按体重随机分为6组：空白组、模型组、阳性药组、RJYZ1组、RJYZ2组、对照药组，阳性药采用石杉碱甲，人临床最大日用量为450μg/d，小鼠给药剂量采用临床最大日用量的10倍，即75μg/kg×day
-1。动物按体重连续灌胃给药10d，空白及模型组给予相应体积溶剂，末次给药后1h开始进行跳台实验训练，训练5min，24h后测试记忆成绩，模型组及各给药组于测试前30min灌胃给予40％乙醇10ml/kg，空白组小鼠灌胃相应体积蒸馏水，观察并记录5min内第一次跳下平台的潜伏期和错误次数，作为记忆指标。【结果】与空白组比较，模型组小鼠潜伏期明显缩短(P<0.05)，错误次数明显增加(P<0.01)，此二指标显示乙醇造模成功；与模型组比较，对照药组小鼠潜伏期与错误次数无显著差异(P>0.05)，RJYZ2组小鼠潜伏期明显延长(P<0.05)，错误次数明显减少(P<0.05)，RJYZ1组也表现出潜伏期明显延长(P<0.05)，错误次数明显减少(P<0.01)。【结论】以上两指标显示本发明药物组合物对乙醇致小鼠记忆再现缺失有一定的改善作用。
[Objective] To observe the improvement effect of the pharmaceutical composition of the present invention on the memory ability of mice with memory loss caused by ethanol. [Method] 72 ICR mice, half male and half male, were randomly divided into 6 groups according to body weight: blank group, model group, positive drug group, RJYZ1 group, RJYZ2 group, and control drug group. The positive drug was huperzine A. The maximum daily dosage is 450 μg/d, and the dosage for mice is 10 times of the clinical maximum daily dosage, that is, 75 μg/kg×day -1 . Animals were given continuous intragastric administration according to their body weight for 10 days, and corresponding volumes of solvent were given to the blank and model groups. The platform jumping test training was started 1 hour after the last administration, and the training was carried out for 5 minutes. After 24 hours, the memory scores were tested. The model group and each drug group were given 30 minutes before the test. 40% ethanol 10ml/kg was given by intragastric administration, and the corresponding volume of distilled water was intragastrically administered to the mice in the blank group. The latency period and the number of mistakes of jumping off the platform for the first time within 5 minutes were observed and recorded as memory indicators. 【Result】Compared with the blank group, the incubation period of the mice in the model group was significantly shortened (P<0.05), and the number of mistakes was significantly increased (P<0.01). These two indicators showed that the ethanol model was successfully established; There was no significant difference between the latency and the number of mistakes (P>0.05). The latency of the mice in the RJYZ2 group was significantly prolonged (P<0.05), and the number of mistakes was significantly reduced (P<0.05). The RJYZ1 group also showed a significant extension of the latency (P<0.05). The number of errors was significantly reduced (P<0.01). [Conclusion] The above two indicators show that the pharmaceutical composition of the present invention has a certain improvement effect on the loss of memory reproduction in mice induced by ethanol.
实验目的Purpose
采用乙醇致小鼠记忆再现缺失模型，观察本发明药物组合物对记忆再现缺失小鼠学习记忆能力的改善作用。The mouse model of memory loss caused by ethanol is used to observe the improvement effect of the pharmaceutical composition of the present invention on the learning and memory ability of the memory loss mouse.
1实验材料1 Experimental materials
1.1供试品(与试验1供试品相同)1.1 Test product (same as test 1 test product)
1.2阳性药、工具药及主要试剂1.2 Positive drugs, tool drugs and main reagents
哈伯因(石杉碱甲片)：河南太龙药业股份有限公司，批号：140902。Haberin (Huperzine A Tablets): Henan Tailong Pharmaceutical Co., Ltd., batch number: 140902.
95％乙醇：天津市富起化工有限公司，批号：131028。95% ethanol: Tianjin Fuqi Chemical Co., Ltd., batch number: 131028.
苦味酸：台山市粤侨试剂塑料有限公司，批号：20131001。Picric acid: Taishan Yueqiao Reagent Plastic Co., Ltd., batch number: 20131001.
1.3实验系统1.3 Experimental system
1.3.1动物种系：ICR小鼠。1.3.1 Animal strain: ICR mice.
1.3.2动物级别：SPF级。1.3.2 Animal grade: SPF grade.
1.3.3动物性别和数量：雌雄各半，共72只。1.3.3 Sex and number of animals: half male and half male, 72 animals in total.
1.3.4动物年龄：4周龄。1.3.4 Animal age: 4 weeks old.
1.3.5动物体重：16～20g。1.3.5 Animal weight: 16-20g.
1.3.6动物来源：购于北京维通利华实验动物技术有限公司，合格证号：1140700091998，许可证号：SCXK(京)2012-0001，接收日期2015年4月22日。1.3.6 Animal source: purchased from Beijing Weitong Lihua Experimental Animal Technology Co., Ltd., certificate number: 1140700091998, license number: SCXK (Beijing) 2012-0001, and the date of receipt was April 22, 2015.
1.3.7饲养条件：动物饲养于河北省中西医结合医药研究院新药评价中心。光照12小时/天，温度20～26℃，相对湿度40～70％。小鼠笼养，6只/笼。1.3.7 Raising conditions: Animals were raised in the New Drug Evaluation Center of Hebei Academy of Integrated Traditional Chinese and Western Medicine. The light is 12 hours/day, the temperature is 20-26°C, and the relative humidity is 40-70%. Mice were housed in cages, 6/cage.
1.3.8检疫过程：新动物检疫期3天，检疫期间动物饮水和摄食正常，健康状况良好，无疾病和死亡征兆。1.3.8 Quarantine process: The quarantine period for new animals is 3 days. During the quarantine period, the animals drink water and eat normally, are in good health, and have no signs of disease or death.
1.3.9饲料：实验级颗粒鼠粮，江苏省协同医药生物工程有限责任公司提供，生产许可证：苏饲审(2014)01008。1.3.9 Feed: experimental-grade granular mouse food, provided by Jiangsu Synergy Pharmaceutical Bioengineering Co., Ltd., production license: Su Wei Shen (2014) 01008.
1.3.10饮水：灌装普通用水供动物自由饮用，每日冲洗饮水瓶并换水一次。1.3.10 Drinking water: fill with ordinary water for animals to drink freely, rinse the drinking water bottle and change the water once a day.
1.3.11垫料：实验动物普通级垫料，由河北省实验动物中心提供，生产许可证：SCXK(冀)2013-2-001。1.3.11 Bedding: Common grade bedding for experimental animals, provided by Hebei Experimental Animal Center, production license: SCXK (Ji) 2013-2-001.
1.3.12标识：5％苦味酸标记。1.3.12 Label: 5% picric acid label.
2实验方法2 Experimental methods
2.1实验设计依据2.1 Experimental Design Basis
2.1.1采用标准：中华人民共和国卫生部药政管理局颁布的中药新药研究指南(药学，药理学，毒理学)、新药(西药)临床前研究指导原则汇编(药学，药理学，毒理学)，人民卫生出版社出版的《中药药理研究方法学》、《药理实验方法学》及相关文献资料确定。2.1.1 Standards used: Guidelines for New Drug Research of Traditional Chinese Medicine (Pharmacy, Pharmacology, Toxicology) and Guidelines for Preclinical Research of New Drugs (Western Medicine) issued by the Drug Administration of the Ministry of Health of the People's Republic of China (Pharmacy, Pharmacology, Toxicology) , "Chinese Medicine Pharmacological Research Methodology" and "Pharmacological Experimental Methodology" published by People's Health Publishing House and related literature.
2.1.2委托单位提供资料：RJYZ拟临床人用量为24.0g生药/天，人按60kg体重计算，则拟临床使用剂量为0.4g生药/kg，供试品干膏粉含量为5.0g生药/g干膏粉，批号20150406。2.1.2 Information provided by the entrusting unit: RJYZ’s proposed clinical dosage for humans is 24.0g of crude drug/day, calculated on the basis of 60kg body weight, the proposed clinical dosage is 0.4g of crude drug/kg, and the content of the dry ointment powder of the test product is 5.0g of crude drug/day g dry cream powder, batch number 20150406.
2.2剂量与分组2.2 Dosage and grouping
小鼠按体重随机分为6组，即空白组、模型组、阳性药(石杉碱甲)组、RJYZ1组、RJYZ2组、对照药组，每组12只，RJYZ1组、RJYZ2组、对照药组拟定为4.0生药/kg×day
-1，相 当于临床人用剂量的10倍，石杉碱甲临床最大日用量(9片)为450μg/人/天，小鼠给药剂量为临床最大日用量的10倍，即75μg/kg×day
-1。见表5。
Mice were randomly divided into 6 groups according to body weight, namely blank group, model group, positive drug (huperzine A) group, RJYZ1 group, RJYZ2 group, control drug group, 12 in each group, RJYZ1 group, RJYZ2 group, control drug group The group is planned to be 4.0 crude drug/kg×day -1 , which is equivalent to 10 times the clinical human dose. The maximum clinical daily dose of huperzine A (9 tablets) is 450 μg/person/day, and the dose for mice is the clinical maximum daily dose. 10 times the dosage, that is, 75μg/kg×day -1 . See Table 5.
表5 RJYZ对乙醇致小鼠记忆再现缺失模型的影响实验分组及给药剂量对照表Table 5 Effect of RJYZ on ethanol-induced memory loss model in mice
2.3给药方法2.3 Administration method
灌胃给药，与临床推荐的口服途径相一致。Oral administration is consistent with the clinically recommended oral route.
2.4供试品配制和保存2.4 Preparation and storage of the test product
各受试药用蒸馏水配制成实验用浓度(见表5)，配制后置2～8℃保存备用，阳性药现用现配。The distilled water of each test drug was prepared to the experimental concentration (see Table 5), and after preparation, it was stored at 2-8°C for future use, and the positive drug was prepared immediately after use.
2.5供试品的给予2.5 Administration of the test article
动物按10ml/kg灌胃给药，空白组及模型组给予蒸馏水，每日给药1次连续10d。Animals were given intragastric administration of 10ml/kg, and the blank group and model group were given distilled water, once a day for 10 consecutive days.
2.6步骤、观测指标2.6 Steps, observation indicators
小鼠跳台装置为六个长方形反射箱，大小为32cm*22.5cm*33cm，用黑色塑料板分隔成为6间，底面为不锈钢网栅，网栅间距为0.5cm，每间左后角放置一高和直径4.5cm的橡胶站台，将小鼠面向墙角轻轻放置与站台上，适应环境3min，然后通以36V电流，若动物跳下站台则受电击，其正常反应应该是跳回站台以躲避伤害性刺激，多数动物可能会再次或多次跳至网栅上逃避电击，跳下时以小鼠双足同时接触铜栅为触电，视为错误次数，训练5min，24h后进行测试，此即记忆保持测验，记录5min内第一次跳下平台的潜伏期和错误次数。The mouse jumping platform device consists of six rectangular reflection boxes with a size of 32cm*22.5cm*33cm. They are divided into 6 rooms with black plastic plates. The bottom surface is a stainless steel grid with a grid spacing of 0.5cm. And a rubber platform with a diameter of 4.5cm, place the mouse on the platform gently facing the corner, adapt to the environment for 3 minutes, and then pass a 36V current. If the animal jumps off the platform, it will be shocked. Its normal reaction should be to jump back to the platform to avoid injury Sexual stimulation, most animals may jump to the grid again or several times to escape the electric shock. When jumping, the mouse’s feet touch the copper grid at the same time as the electric shock, which is regarded as the number of errors. After training for 5 minutes, test it after 24 hours, which is memory. Keep the test, record the latency and the number of mistakes when jumping off the platform for the first time within 5 minutes.
新接收动物标号，检疫3d，检疫完成后动物按体重随机分为6组，如前所述。按体重灌胃给药，每日一次，连续10d，空白组及模型组给予蒸馏水，末次给药后1h开始进行跳台训练，训练5min，24h后测试记忆成绩，模型组及各给药组于测试前30min灌胃给予40％乙醇10ml/kg，空白组小鼠灌胃相应体积蒸馏水，观察并记录5min内第一次跳下平台的潜伏期和错误次数，5min内未跳下的小鼠其跳台潜伏期按300s计算。Newly received animals were labeled and quarantined for 3 days. After the quarantine was completed, the animals were randomly divided into 6 groups according to body weight, as described above. Oral administration according to body weight, once a day, for 10 consecutive days, distilled water was given to the blank group and the model group, platform training was started 1 hour after the last administration, and the training was performed for 5 minutes, and memory scores were tested after 24 hours. In the first 30 minutes, 40% ethanol 10ml/kg was given by intragastric administration, and the corresponding volume of distilled water was administered to the mice in the blank group. The latency period and the number of mistakes for the first jump off the platform within 5 minutes were observed and recorded, and the platform jump latency of the mice that did not jump off the platform within 5 minutes Calculated by 300s.
2.7相关工作人员通知2.7 Relevant staff notification
购买动物时通知动物室，在动物出现异常情况时通知病理室进行处理。Notify the animal room when purchasing animals, and notify the pathology room for processing when animals appear abnormal.
2.8仪器系统2.8 Instrument system
DT2000电子天平，常熟双杰测试仪器厂。DT2000 electronic balance, Changshu Shuangjie Test Instrument Factory.
SL-2001N电子天平，上海民桥精密科学仪器有限公司。SL-2001N electronic balance, Shanghai Minqiao Precision Scientific Instrument Co., Ltd.
秒表，深圳市惠波工贸有限公司。Stopwatch, Shenzhen Huibo Industry and Trade Co., Ltd.
DT200小鼠跳台仪，成都泰盟科技有限公司。DT200 mouse jumping platform, Chengdu Taimeng Technology Co., Ltd.
2.9统计方法2.9 Statistical methods
实验数据采用SPSS11.5统计软件进行分析处理，统计结果用均数±标准差
表示，首先进行正态性检验，符合正态分布的数据，均数比较用单因素方差分析(One-WayANOVA)，若方差齐，两两比较采用最小显著差法(LSD)，若方差不齐则采用Dunnett’s T3检验行两两比较；如不符合正态分布，则用非参数检验进行统计分析。
The experimental data is analyzed and processed by SPSS11.5 statistical software, and the statistical results are expressed as mean ± standard deviation It means that firstly, the normality test is carried out, and the data conforming to the normal distribution are compared with one-way analysis of variance (One-WayANOVA). If the variances are equal, the least significant difference method (LSD) is used for pairwise comparison. The Dunnett's T3 test was used for pairwise comparison; if the normal distribution was not met, the non-parametric test was used for statistical analysis.
3结果3 results
由表6可见，与空白组比较，模型组小鼠潜伏期明显缩短(P<0.05)，错误次数明显增加(P<0.01)，此二指标显示乙醇造模成功；与模型组比较，对照药组小鼠潜伏期与错误次数无显著差异(P>0.05)，RJYZ2组小鼠潜伏期明显延长(P<0.05)，错误次数明显减少(P<0.05)，RJYZ1组也表现出潜伏期明显延长(P<0.05)，错误次数明显减少(P<0.01)。As can be seen from Table 6, compared with the blank group, the incubation period of the mice in the model group was significantly shortened (P<0.05), and the number of mistakes was significantly increased (P<0.01). These two indicators showed that the ethanol model was successfully established; There was no significant difference between the latency of the mice and the number of mistakes (P>0.05), the latency of the mice in the RJYZ2 group was significantly prolonged (P<0.05), and the number of mistakes was significantly reduced (P<0.05), and the latency of the RJYZ1 group was also significantly prolonged (P<0.05 ), the number of mistakes was significantly reduced (P<0.01).
表6 RJYZ对乙醇致小鼠记忆再现缺失模型的影响跳台结果
Table 6 The effect of RJYZ on the ethanol-induced memory loss model in mice
注：与空白组比较：
△P＜0.05，
△△P＜0.01；与模型组比较：*P＜0.05，**P＜0.01。
Note: Compared with the blank group: △ P<0.05, △△ P<0.01; compared with the model group: *P<0.05, **P<0.01.
4结论4 Conclusion
本实验结果表明本发明药物组合物对乙醇致小鼠记忆再现缺失有一定的改善作用。The results of this experiment show that the pharmaceutical composition of the present invention has a certain effect on improving the loss of memory and reproduction in mice induced by ethanol.
5讨论5 discussions
学习记忆障碍是老年痴呆的一种重要表现，是人类和动物赖以生存所不可缺少的重要脑功能之一，学习是神经系统接受外界环境变化获得新行为和经验的过程，记忆是学习后经验的保持和再现。一般把学习记忆分为3个阶段，即获得、巩固和再现，乙醇为中枢神经抑制剂，是常用的记忆再现缺失模型的工具药，其可抑制动物的条件反射过程，使脑内蛋白质和RNA合成受阻，以及胆碱能和多巴胺等系统发生改变，从而破坏学习记忆功能。Impairment of learning and memory is an important manifestation of senile dementia, and it is one of the important brain functions that are indispensable for the survival of humans and animals. Learning is the process by which the nervous system accepts changes in the external environment to acquire new behaviors and experiences. Memory is the experience after learning. maintenance and reproduction. Generally, learning and memory are divided into three stages, that is, acquisition, consolidation and reproduction. Ethanol is a central nervous system inhibitor, and it is a commonly used tool drug for memory and reproduction loss models. It can inhibit the conditioned reflex process of animals and make protein and RNA in the brain Synthesis is blocked, and systems such as cholinergic and dopamine are altered, thereby disrupting learning and memory functions.
跳台实验是常用的测试学习记忆的行为学方法，但其准确度易受诸多因素的影响，如实验环境、实验动物、非特异性干扰、奖励和惩罚效应等，Platform jumping test is a commonly used behavioral method for testing learning and memory, but its accuracy is easily affected by many factors, such as experimental environment, experimental animals, non-specific interference, reward and punishment effects, etc.
本次实验中借鉴了本实验室前期积累的经验，实验中对动物进食量加以控制，使体重不至于偏大，减少因体重过大致上台困难的影响，以及保持安静的实验环境，室内温湿度、光照适宜并保持一致等。本实验结果显示了中药复方RJYZ潜伏期、错误次数较模型组有显著差异，且有一定剂量依赖性，表明中药复方RJYZ对乙醇致小鼠记忆再现缺失模型有一定的改善作用。In this experiment, the experience accumulated in the previous laboratory was used for reference. In the experiment, the food intake of the animals was controlled so that the body weight would not be too large, and the influence of difficulty in getting on stage due to overweight was reduced, and the experimental environment was kept quiet, and the indoor temperature and humidity , Lighting is appropriate and consistent. The results of this experiment showed that the latency period and the number of errors of the traditional Chinese medicine compound RJYZ were significantly different from those of the model group, and there was a certain dose dependence, indicating that the traditional Chinese medicine compound RJYZ had a certain improvement effect on the model of alcohol-induced memory loss in mice.
试验3：Trial 3:
本发明药物组合物对亚硝酸钠致小鼠记忆巩固障碍模型的影响Effect of the pharmaceutical composition of the present invention on sodium nitrite-induced memory consolidation disorder model in mice
摘要Summary
【目的】采用亚硝酸钠致小鼠记忆巩固障碍模型，观察本发明药物组合物对记忆巩固障碍小鼠学习、记忆能力的改善作用。【方法】96只ICR小鼠雌雄各半，按体重随机分为6组：空白组、模型组、阳性药组、RJYZ1组、RJYZ2组、对照药组，RJYZ1组、RJYZ2组、对照药组给药量为4.0g生药/kg×day
-1，相当于临床人用剂量的10倍，阳性药采用石杉碱甲，人临床最大日用量为450μg/d，小鼠给药剂量采用临床最大日用量的10倍，即75μg/kg×day
-1。动物按体重连续灌胃给药10d，空白及模型组给予相应体积溶剂，末次给药后1h开始进行跳台实验训练，训练5min，训练结束后模型组及各给药组立即皮下注射亚硝酸钠120mg/kg，体积为10ml/kg，空白组小鼠给予相应体积生理盐水，24h后测试记忆成绩，观察并记录5min内第一次跳下平台的潜伏期和错误次数，作为记忆指标。【结果】与空白组比较，模型组小鼠潜伏期明显缩短(P<0.05)，错误次数明显增加(P<0.05)，此二指标显示亚硝酸钠造模成功；与模型组比较，对照药组小鼠潜伏期与错误次数无显著差异(P>0.05)，RJYZ2组小鼠潜伏期明显延长(P<0.05)，错误次数明显减少(P<0.05)，RJYZ1组也表现出潜伏期明显延长(P<0.05)，错误次数明显减少(P<0.05)。【结论】以上两指标显示本发明药物组合物对亚硝酸钠致小鼠记忆巩固障碍有一定的改善作用。
[Objective] To observe the improvement effect of the pharmaceutical composition of the present invention on the learning and memory ability of mice with memory consolidation disorder by using sodium nitrite-induced memory consolidation disorder model in mice. [Method] 96 ICR mice, half male and half male, were randomly divided into 6 groups according to body weight: blank group, model group, positive drug group, RJYZ1 group, RJYZ2 group, control drug group, RJYZ1 group, RJYZ2 group, and control drug group. The dosage is 4.0g crude drug/kg×day -1 , which is equivalent to 10 times the clinical human dose. The positive drug is huperzine A. The maximum clinical daily dosage for humans is 450μg/d, and the maximum clinical daily dosage for mice is 450μg/d. 10 times the dosage, that is, 75μg/kg×day -1 . Animals were given continuous intragastric administration for 10 days according to their body weight, and corresponding volumes of solvent were given to the blank and model groups. The platform jumping test training was started 1 hour after the last administration, and the training was 5 minutes. After the training, the model group and each drug group were immediately subcutaneously injected with 120 mg of sodium nitrite /kg, the volume is 10ml/kg, the mice in the blank group are given corresponding volume of normal saline, and the memory performance is tested after 24 hours, and the latency period and the number of mistakes of jumping off the platform for the first time within 5 minutes are observed and recorded as memory indicators. 【Result】Compared with the blank group, the incubation period of the mice in the model group was significantly shortened (P<0.05), and the number of mistakes was significantly increased (P<0.05). There was no significant difference between the latency of the mice and the number of mistakes (P>0.05), the latency of the mice in the RJYZ2 group was significantly prolonged (P<0.05), and the number of mistakes was significantly reduced (P<0.05), and the latency of the RJYZ1 group was also significantly prolonged (P<0.05 ), the number of mistakes was significantly reduced (P<0.05). [Conclusion] The above two indicators show that the pharmaceutical composition of the present invention has a certain improvement effect on sodium nitrite-induced memory consolidation disorder in mice.
实验目的Purpose
采用亚硝酸钠致小鼠记忆巩固障碍模型，观察本发明药物组合物对记忆巩固障碍小鼠学习记忆能力的改善作用。The sodium nitrite-induced memory consolidation disorder model is used to observe the improvement effect of the pharmaceutical composition of the present invention on the learning and memory ability of the memory consolidation disorder mice.
1实验材料1 Experimental materials
1.1供试品(与试验1供试品相同)1.1 Test product (same as test 1 test product)
1.2阳性药、工具药及主要试剂1.2 Positive drugs, tool drugs and main reagents
哈伯因(石杉碱甲片)：河南太龙药业股份有限公司，批号：140902。Haberin (Huperzine A Tablets): Henan Tailong Pharmaceutical Co., Ltd., batch number: 140902.
亚硝酸钠：天津博迪化工股份有限公司，批号：20131113。Sodium nitrite: Tianjin Bodi Chemical Co., Ltd., batch number: 20131113.
苦味酸：台山市粤侨试剂塑料有限公司，批号：20131001。Picric acid: Taishan Yueqiao Reagent Plastic Co., Ltd., batch number: 20131001.
1.3实验系统1.3 Experimental system
1.3.1动物种系：ICR小鼠。1.3.1 Animal strain: ICR mice.
1.3.2动物级别：SPF级。1.3.2 Animal grade: SPF grade.
1.3.3动物性别和数量：雌雄各半，共96只。1.3.3 Sex and number of animals: half male and half male, 96 animals in total.
1.3.4动物年龄：4周龄。1.3.4 Animal age: 4 weeks old.
1.3.5动物体重：16～20g。1.3.5 Animal weight: 16-20g.
1.3.6动物来源：购于北京维通利华实验动物技术有限公司，合格证号：11400700095243，许可证号：SCXK(京)2012-0001，接收日期2015年5月13日。1.3.6 Animal source: purchased from Beijing Weitong Lihua Experimental Animal Technology Co., Ltd., certificate number: 11400700095243, license number: SCXK (Beijing) 2012-0001, and the date of receipt was May 13, 2015.
1.3.7饲养条件：动物饲养于河北省中西医结合医药研究院新药评价中心。小鼠笼养，光照12小时/天，温度20～26℃，相对湿度40～70％。1.3.7 Raising conditions: Animals were raised in the New Drug Evaluation Center of Hebei Academy of Integrated Traditional Chinese and Western Medicine. The mice were housed in a cage with 12 hours of light per day, a temperature of 20-26° C., and a relative humidity of 40-70%.
1.3.8检疫过程：新动物检疫期5天，检疫期间动物饮水和摄食正常，健康状况良好，无疾病和死亡征兆。1.3.8 Quarantine process: The quarantine period for new animals is 5 days. During the quarantine period, the animals drink water and eat normally, are in good health, and have no signs of disease or death.
1.3.9饲料：实验级颗粒鼠粮，江苏省协同医药生物工程有限责任公司提供，生产许可证：苏饲审(2014)01008。1.3.9 Feed: experimental-grade granular mouse food, provided by Jiangsu Synergy Pharmaceutical Bioengineering Co., Ltd., production license: Su Wei Shen (2014) 01008.
1.3.10饮水：灌装普通用水供动物自由饮用，每日冲洗饮水瓶并换水一次。1.3.10 Drinking water: fill with ordinary water for animals to drink freely, rinse the drinking water bottle and change the water once a day.
1.3.11垫料：实验动物普通级垫料，由河北省实验动物中心提供，生产许可证：SCXK(冀)2013-2-001。1.3.11 Bedding: Common grade bedding for experimental animals, provided by Hebei Experimental Animal Center, production license: SCXK (Ji) 2013-2-001.
1.3.12标识：5％苦味酸标记。1.3.12 Label: 5% picric acid label.
2实验方法2 Experimental methods
2.1实验设计依据2.1 Experimental Design Basis
2.1.1采用标准：中华人民共和国卫生部药政管理局颁布的中药新药研究指南(药学，药理学，毒理学)、新药(西药)临床前研究指导原则汇编(药学，药理学，毒理学)，人民卫生出版社出版的《中药药理研究方法学》、《药理实验方法学》及相关文献资料确定。2.1.1 Standards used: Guidelines for New Drug Research of Traditional Chinese Medicine (Pharmacy, Pharmacology, Toxicology) and Guidelines for Preclinical Research of New Drugs (Western Medicine) issued by the Drug Administration of the Ministry of Health of the People's Republic of China (Pharmacy, Pharmacology, Toxicology) , "Chinese Medicine Pharmacological Research Methodology" and "Pharmacological Experimental Methodology" published by People's Health Publishing House and related literature.
2.1.2委托单位提供资料：RJYZ拟临床人用量为24.0g生药/天，人按60kg体重计算，则拟临床使用剂量为0.4g生药/kg，供试品干膏粉含量为5.0g生药/g干膏粉，批号20150406。2.1.2 Information provided by the entrusting unit: RJYZ’s proposed clinical dosage for humans is 24.0g of crude drug/day, calculated on the basis of 60kg body weight, the proposed clinical dosage is 0.4g of crude drug/kg, and the content of the dry ointment powder of the test product is 5.0g of crude drug/day g dry cream powder, batch number 20150406.
2.2剂量与分组2.2 Dosage and grouping
小鼠按体重随机分为6组，即空白组、模型组、阳性药(石杉碱甲)组、RJYZ低、中、高剂量组，每组16只，RJYZ1组、RJYZ2组、对照药组拟定为4.0g生药/kg×day
-1，相当于临床人用剂量的10倍，石杉碱甲临床最大日用量(9片)为450μg/人/天，小鼠给药剂量为 临床最大日用量的10倍，即75μg/kg×day
-1。见表7。
Mice were randomly divided into 6 groups according to body weight, namely blank group, model group, positive drug (huperzine A) group, RJYZ low, medium and high dose groups, 16 in each group, RJYZ1 group, RJYZ2 group, control drug group It is planned to be 4.0g crude drug/kg×day -1 , which is equivalent to 10 times the clinical human dose. The maximum clinical daily dose of huperzine A (9 tablets) is 450μg/person/day, and the clinical maximum daily dose for mice is 10 times the dosage, that is, 75μg/kg×day -1 . See Table 7.
表7 RJYZ对亚硝酸钠致小鼠记忆巩固障碍模型的影响实验分组及给药剂量对照表Table 7 Effect of RJYZ on Sodium Nitrite-Induced Memory Consolidation Impairment Model in Experimental Grouping and Dosage Comparison Table
2.3给药方法2.3 Administration method
灌胃给药，与临床推荐的口服途径相一致。Oral administration is consistent with the clinically recommended oral route.
2.4供试品配制和保存2.4 Preparation and storage of the test product
各受试药用蒸馏水配制成实验用浓度(见表7)，配制后置2～8℃保存备用，阳性药现用现配。Each test drug was prepared with distilled water to the concentration used in the experiment (see Table 7). After preparation, it was stored at 2-8°C for future use, and the positive drug was prepared immediately after use.
2.5供试品的给予2.5 Administration of the test article
动物按10ml/kg灌胃给药，空白组及模型组给予蒸馏水，每日给药1次连续10d。Animals were given intragastric administration of 10ml/kg, and the blank group and model group were given distilled water, once a day for 10 consecutive days.
2.6步骤、观测指标2.6 Steps, observation indicators
小鼠跳台装置为六个长方形反射箱，大小为32cm*22.5cm*33cm，用黑色塑料板分隔成为6间，底面为不锈钢网栅，网栅间距为0.5cm，每间左后角放置一高和直径4.5cm的橡胶站台，将小鼠面向墙角轻轻放置与站台上，适应环境3min，然后通以36V电流，若动物跳下站台则受电击，其正常反应应该是跳回站台以躲避伤害性刺激，多数动物可能会再次或多次跳至网栅上逃避电击，跳下时以小鼠双足同时接触铜栅为触电，视为错误次数，训练5min，24h后进行测试，此即记忆保持测验，记录5min内第一次跳下平台的潜伏期和错误次数。The mouse jumping platform device consists of six rectangular reflection boxes with a size of 32cm*22.5cm*33cm. They are divided into 6 rooms with black plastic plates. The bottom surface is a stainless steel grid with a grid spacing of 0.5cm. And a rubber platform with a diameter of 4.5cm, place the mouse on the platform gently facing the corner, adapt to the environment for 3 minutes, and then pass a 36V current. If the animal jumps off the platform, it will be shocked. Its normal reaction should be to jump back to the platform to avoid injury Sexual stimulation, most animals may jump to the grid again or several times to escape the electric shock. When jumping, the mouse’s feet touch the copper grid at the same time as the electric shock, which is regarded as the number of errors. After training for 5 minutes, test it after 24 hours, which is memory. Keep the test, record the latency and the number of mistakes when jumping off the platform for the first time within 5 minutes.
新接收动物标号，检疫5d，检疫完成后动物按体重随机分为6组，如前所述。按体重灌胃给药，每日一次，连续10d，空白组及模型组给予蒸馏水，末次给药后1h开始进行跳台训练，训练5min，训练结束后模型组及各给药组立即皮下注射亚硝酸钠120mg/kg，体积为10ml/kg，空白组小鼠给予相应体积生理盐水，24h后测试记忆成绩，观察并记录5min内第一次跳下平台的潜伏期和错误次数，5min内未跳下的小鼠其跳台潜伏期按300s计算。Newly received animals were labeled and quarantined for 5 days. After the quarantine was completed, the animals were randomly divided into 6 groups according to body weight, as described above. Oral administration according to body weight, once a day, for 10 consecutive days, distilled water was given to the blank group and the model group, platform training was started 1 hour after the last administration, and the training was 5 minutes. Immediately after the training, the model group and each drug group were injected with nitrous acid Sodium 120mg/kg, the volume is 10ml/kg, the mice in the blank group were given corresponding volume of normal saline, after 24 hours, the memory performance was tested, the latency period and the number of mistakes when jumping off the platform for the first time within 5 minutes were observed and recorded, and those who did not jump off within 5 minutes The platform jumping latency of mice is calculated as 300s.
2.7相关工作人员通知2.7 Relevant staff notification
购买动物时通知动物室，在动物出现异常情况时通知病理室进行处理。Notify the animal room when purchasing animals, and notify the pathology room for processing when animals appear abnormal.
2.8仪器系统2.8 Instrument system
DT2000电子天平，常熟双杰测试仪器厂。DT2000 electronic balance, Changshu Shuangjie Test Instrument Factory.
SL-2001N电子天平，上海民桥精密科学仪器有限公司。SL-2001N electronic balance, Shanghai Minqiao Precision Scientific Instrument Co., Ltd.
AL204梅特勒精密分析天平，梅特勒-托利多(上海)有限公司。AL204 Mettler precision analytical balance, Mettler-Toledo (Shanghai) Co., Ltd.
秒表，深圳市惠波工贸有限公司。Stopwatch, Shenzhen Huibo Industry and Trade Co., Ltd.
DT200小鼠跳台仪，成都泰盟科技有限公司。DT200 mouse jumping platform, Chengdu Taimeng Technology Co., Ltd.
2.9统计方法2.9 Statistical methods
实验数据采用SPSS11.5统计软件进行分析处理，统计结果用均数±标准差
表示，首先进行正态性检验，符合正态分布的数据，均数比较用单因素方差分析(One-Way ANOVA)，若方差齐，两两比较采用最小显著差法(LSD)，若方差不齐则采用Dunnett’s T3检验行两两比较；如不符合正态分布，则用非参数检验进行统计分析。
The experimental data is analyzed and processed by SPSS11.5 statistical software, and the statistical results are expressed as mean ± standard deviation It means that the normality test is carried out first, and the data conforming to the normal distribution are compared with one-way analysis of variance (One-Way ANOVA). If the variances are equal, the least significant difference method (LSD) is used for pairwise comparison. For Qi, the Dunnett's T3 test was used for pairwise comparison; if the normal distribution was not met, the non-parametric test was used for statistical analysis.
3结果3 results
由表8可见，与空白组比较，模型组小鼠潜伏期明显缩短(P<0.05)，错误次数明显增加(P<0.05)，此二指标显示亚硝酸钠造模成功；与模型组比较，对照药组小鼠潜伏期与错误次数无显著差异(P>0.05)，RJYZ2组小鼠潜伏期明显延长(P<0.05)，错误次数明显减少(P<0.05)，RJYZ1组也表现出潜伏期明显延长(P<0.05)，错误次数明显减少(P<0.05)。As can be seen from Table 8, compared with the blank group, the incubation period of the mice in the model group was significantly shortened (P<0.05), and the number of mistakes was significantly increased (P<0.05). These two indicators showed that sodium nitrite was successful in modeling; There was no significant difference between the latency and the number of mistakes in the drug group (P>0.05), the latency of the mice in the RJYZ2 group was significantly prolonged (P<0.05), and the number of mistakes was significantly reduced (P<0.05), and the RJYZ1 group also showed a significant extension of the latency (P<0.05). <0.05), the number of errors was significantly reduced (P<0.05).
表8 RJYZ对亚礀酸钠致小鼠记忆巩固障碍模型的影响实验跳台结果
Table 8 The effect of RJYZ on sodium hypochlorite-induced memory consolidation disorder model in mice
注：与空白组比较：
△P＜0.05，
△△P＜0.01；与模型组比较：*P＜0.05，**P＜0.01。
Note: Compared with the blank group: △ P<0.05, △△ P<0.01; compared with the model group: *P<0.05, **P<0.01.
4结论4 Conclusion
本实验结果说明了本发明药物组合物对亚硝酸钠致小鼠记忆巩固障碍有一定的改善作用。The results of this experiment illustrate that the pharmaceutical composition of the present invention has a certain improvement effect on sodium nitrite-induced memory consolidation disorder in mice.
5讨论5 discussions
学习记忆障碍是老年痴呆的一种重要表现，是人类和动物赖以生存所不可缺少的重要脑功能之一，学习是神经系统接受外界环境变化获得新行为和经验的过程，记忆是学习后经验的保持和再现。一般把学习记忆分为3个阶段，即获得、巩固和再现，亚硝酸盐大量进入机体后，可使正常的血红蛋白变为高铁血红蛋白，失去携氧能力，引起组织缺氧，神经细胞受损，可引起动物记忆巩固障碍。Impairment of learning and memory is an important manifestation of senile dementia, and it is one of the important brain functions that are indispensable for the survival of humans and animals. Learning is the process by which the nervous system accepts changes in the external environment to acquire new behaviors and experiences. Memory is the experience after learning. maintenance and reproduction. Generally, learning and memory are divided into three stages, that is, acquisition, consolidation and reproduction. After a large amount of nitrite enters the body, normal hemoglobin can be changed into methemoglobin, which will lose the ability to carry oxygen, cause tissue hypoxia, and damage nerve cells. Can cause memory consolidation disorders in animals.
跳台实验是常用的测试学习记忆的行为学方法，但其准确度易受诸多因素的影响，如实 验环境、实验动物、非特异性干扰、奖励和惩罚效应等，Platform jumping test is a commonly used behavioral method for testing learning and memory, but its accuracy is easily affected by many factors, such as experimental environment, experimental animals, non-specific interference, reward and punishment effects, etc.
本次实验中借鉴了本实验室前期积累的经验，实验中对动物进食量加以控制，使体重不至于偏大，减少因体重过大致上台困难的影响，以及保持安静的实验环境，室内温湿度、光照适宜并保持一致等。本实验结果显示了中药复方RJYZ潜伏期、错误次数较模型组有显著差异，且有一定剂量依赖性，表明中药复方RJYZ对亚硝酸钠致小鼠记忆巩固障碍有一定的改善作用。In this experiment, the experience accumulated in the previous laboratory was used for reference. In the experiment, the food intake of the animals was controlled so that the body weight would not be too large, and the influence of difficulty in getting on stage due to overweight was reduced, and the experimental environment was kept quiet, and the indoor temperature and humidity , Lighting is appropriate and consistent. The results of this experiment showed that the latency period and the number of mistakes of the Chinese medicine compound RJYZ were significantly different from those of the model group, and there was a certain dose dependence, indicating that the Chinese medicine compound RJYZ had a certain effect on improving the memory consolidation disorder in mice induced by sodium nitrite.
试验4：Test 4:
本发明药物组合物对东莨菪碱致小鼠记忆获得障碍模型的影响Influence of the pharmaceutical composition of the present invention on the memory acquisition disorder model of mice induced by scopolamine
摘要Summary
【目的】采用东莨菪碱致小鼠记忆获得障碍模型，观察本发明药物组合物对记忆获得障碍小鼠学习记忆能力的改善作用。【方法】96只ICR小鼠雌雄各半，按体重随机分为6组：空白组、模型组、阳性药组、RJYZ1组、RJYZ2组、对照药组，RJYZ1组、RJYZ2组、对照药组给药量为4.0g生药/kg×day
-1，相当于临床人用剂量的10倍，阳性药采用石杉碱甲，人临床最大日用量为450μg/d，小鼠给药剂量采用临床最大日用量的10倍，即75μg/kg×day
-1。动物按体重连续灌胃给药10d，空白及模型组给予相应体积溶剂，末次给药后1h开始进行跳台训练，训练前20min除空白组外各组腹腔注射氢溴酸东莨菪碱3mg/kg，空白组给予相应体积生理盐水，训练5min，24h后测试记忆成绩，观察并记录5min内第一次跳下平台的潜伏期和错误次数，作为记忆指标。【结果】与空白组比较，模型组小鼠潜伏期明显缩短(P<0.05)，错误次数明显增加(P<0.05)，此二指标显示东莨菪碱造模成功；与模型组比较，RJYZ2组小鼠错误次数明显减少(P<0.05)，RJYZ1组潜伏期明显延长(P<0.05)，错误次数明显减少(P<0.05)。【结论】以上两指标显示本发明药物组合物对东莨菪碱致小鼠记忆获得障碍有一定的改善作用。
【Objective】Using scopolamine-induced memory impairment in mice, observe the improvement effect of the pharmaceutical composition of the present invention on the learning and memory ability of memory acquisition impairment mice. [Method] 96 ICR mice, half male and half male, were randomly divided into 6 groups according to body weight: blank group, model group, positive drug group, RJYZ1 group, RJYZ2 group, control drug group, RJYZ1 group, RJYZ2 group, and control drug group. The dosage is 4.0g crude drug/kg×day -1 , which is equivalent to 10 times the clinical human dose. The positive drug is huperzine A. The maximum clinical daily dosage for humans is 450μg/d, and the maximum clinical daily dosage for mice is 450μg/d. 10 times the dosage, that is, 75μg/kg×day -1 . Animals were administered intragastrically for 10 days according to their body weight. The corresponding volume of solvent was given to the blank and model groups. Platform jumping training was started 1 hour after the last administration. Scopolamine hydrobromide 3 mg/kg was injected intraperitoneally into each group except the blank group 20 minutes before training. Give the corresponding volume of normal saline, train for 5 minutes, test the memory performance after 24 hours, observe and record the latency period and the number of mistakes when jumping off the platform for the first time within 5 minutes, as memory indicators. 【Result】Compared with the blank group, the incubation period of the mice in the model group was significantly shortened (P<0.05), and the number of mistakes was significantly increased (P<0.05). The number of times was significantly reduced (P<0.05), the latent period was significantly prolonged (P<0.05), and the number of mistakes was significantly reduced (P<0.05) in the RJYZ1 group. [Conclusion] The above two indicators show that the pharmaceutical composition of the present invention has a certain improvement effect on the impairment of memory acquisition in mice induced by scopolamine.
实验目的Purpose
采用东莨菪碱致小鼠记忆获得障碍模型，观察本发明药物组合物对记忆获得障碍小鼠学习记忆能力的改善作用。Using the memory acquisition disorder model induced by scopolamine in mice, the improvement effect of the pharmaceutical composition of the present invention on the learning and memory ability of the memory acquisition impairment mice is observed.
1实验材料1 Experimental materials
1.1供试品(与试验1供试品相同)1.1 Test product (same as test 1 test product)
1.2阳性药、工具药及主要试剂1.2 Positive drugs, tool drugs and main reagents
哈伯因(石杉碱甲片)：河南太龙药业股份有限公司，批号：140902。Haberin (Huperzine A Tablets): Henan Tailong Pharmaceutical Co., Ltd., batch number: 140902.
氢溴酸东莨菪碱注射液：上海禾丰制药有限公司，批号：02140801。Scopolamine Hydrobromide Injection: Shanghai Hefeng Pharmaceutical Co., Ltd., batch number: 02140801.
苦味酸：台山市粤侨试剂塑料有限公司，批号：20131001。Picric acid: Taishan Yueqiao Reagent Plastic Co., Ltd., batch number: 20131001.
1.3实验系统1.3 Experimental system
1.3.1动物种系：ICR小鼠。1.3.1 Animal strain: ICR mice.
1.3.2动物级别：SPF级。1.3.2 Animal grade: SPF grade.
1.3.3动物性别和数量：雌雄各半，共96只。1.3.3 Sex and number of animals: half male and half male, 96 animals in total.
1.3.4动物年龄：4周龄。1.3.4 Animal age: 4 weeks old.
1.3.5动物体重：16～20g。1.3.5 Animal weight: 16-20g.
1.3.6动物来源：购于北京维通利华实验动物技术有限公司，合格证号：11400700098398，许可证号：SCXK(京)2012-0001，接收日期2015年6月3日。1.3.6 Animal source: purchased from Beijing Weitong Lihua Experimental Animal Technology Co., Ltd., certificate number: 11400700098398, license number: SCXK (Beijing) 2012-0001, and the date of receipt was June 3, 2015.
1.3.7饲养条件：动物饲养于河北省中西医结合医药研究院新药评价中心。小鼠笼养，光照12小时/天，温度20～26℃，相对湿度40～70％。1.3.7 Raising conditions: Animals were raised in the New Drug Evaluation Center of Hebei Academy of Integrated Traditional Chinese and Western Medicine. The mice were housed in a cage with 12 hours of light per day, a temperature of 20-26° C., and a relative humidity of 40-70%.
1.3.8检疫过程：新动物检疫期5天，检疫期间动物饮水和摄食正常，健康状况良好，无疾病和死亡征兆。1.3.8 Quarantine process: The quarantine period for new animals is 5 days. During the quarantine period, the animals drink water and eat normally, are in good health, and have no signs of disease or death.
1.3.9饲料：实验级颗粒鼠粮，江苏省协同医药生物工程有限责任公司提供，生产许可证：苏饲审(2014)01008。1.3.9 Feed: experimental-grade granular mouse food, provided by Jiangsu Synergy Pharmaceutical Bioengineering Co., Ltd., production license: Su Wei Shen (2014) 01008.
1.3.10饮水：灌装普通用水供动物自由饮用，每日冲洗饮水瓶并换水一次。1.3.10 Drinking water: fill with ordinary water for animals to drink freely, rinse the drinking water bottle and change the water once a day.
1.3.11垫料：实验动物普通级垫料，由河北省实验动物中心提供，生产许可证：SCXK(冀)2013-2-001。1.3.11 Bedding: Common grade bedding for experimental animals, provided by Hebei Experimental Animal Center, production license: SCXK (Ji) 2013-2-001.
1.3.12标识：5％苦味酸标记。1.3.12 Label: 5% picric acid label.
2实验方法2 Experimental methods
2.1实验设计依据2.1 Experimental Design Basis
2.1.1采用标准：中华人民共和国卫生部药政管理局颁布的中药新药研究指南(药学，药理学，毒理学)、新药(西药)临床前研究指导原则汇编(药学，药理学，毒理学)，人民卫生出版社出版的《中药药理研究方法学》、《药理实验方法学》及相关文献资料确定。2.1.1 Standards used: Guidelines for New Drug Research of Traditional Chinese Medicine (Pharmacy, Pharmacology, Toxicology) and Guidelines for Preclinical Research of New Drugs (Western Medicine) issued by the Drug Administration of the Ministry of Health of the People's Republic of China (Pharmacy, Pharmacology, Toxicology) , "Chinese Medicine Pharmacological Research Methodology" and "Pharmacological Experimental Methodology" published by People's Health Publishing House and related literature.
2.1.2委托单位提供资料：RJYZ拟临床人用量为24.0g生药/天，人按60kg体重计算，则拟临床使用剂量为0.4g生药/kg，供试品干膏粉含量为5.0g生药/g干膏粉，批号20150406。2.1.2 Information provided by the entrusting unit: RJYZ’s proposed clinical dosage for humans is 24.0g of crude drug/day, calculated on the basis of 60kg body weight, the proposed clinical dosage is 0.4g of crude drug/kg, and the content of the dry ointment powder of the test product is 5.0g of crude drug/day g dry cream powder, batch number 20150406.
2.2剂量与分组2.2 Dosage and grouping
小鼠按体重随机分为6组，即空白组、模型组、阳性药(石杉碱甲)组、RJYZ1组、RJYZ2组、对照药物组，每组16只，RJYZ1组、RJYZ2组、对照药组拟定为4.0g生药/kg×day
-1，相当于临床人用剂量的10倍，石杉碱甲临床最大日用量(9片)为450μg/人/天，小鼠给药 剂量为临床最大日用量的10倍，即75μg/kg×day
-1。见表9。
Mice were randomly divided into 6 groups according to body weight, namely blank group, model group, positive drug (huperzine A) group, RJYZ1 group, RJYZ2 group, control drug group, 16 in each group, RJYZ1 group, RJYZ2 group, control drug group The group is planned to be 4.0g crude drug/kg×day -1 , equivalent to 10 times the clinical human dose, the maximum clinical daily dose of huperzine A (9 tablets) is 450μg/person/day, and the dose for mice is the clinical maximum 10 times the daily dosage, that is, 75μg/kg×day -1 . See Table 9.
表9 RJYZ对东莨菪碱致小鼠记忆获得障碍模型的影响实验分组及给药剂量对照表Table 9 Effect of RJYZ on scopolamine-induced memory acquisition impairment in mice model of experimental grouping and dosage comparison table
2.3给药方法2.3 Administration method
灌胃给药，与临床推荐的口服途径相一致。Oral administration is consistent with the clinically recommended oral route.
2.4供试品配制和保存2.4 Preparation and storage of the test product
各受试药用蒸馏水配制成实验用浓度(见表9)，配制后置2～8℃保存备用，阳性药现用现配。The distilled water of each test drug was prepared to the concentration used in the experiment (see Table 9), and after preparation, it was stored at 2-8°C for future use.
2.5供试品的给予2.5 Administration of the test article
动物按10ml/kg灌胃给药，空白组及模型组给予蒸馏水，每日给药1次连续10d。Animals were given intragastric administration of 10ml/kg, and the blank group and model group were given distilled water, once a day for 10 consecutive days.
2.6步骤、观测指标2.6 Steps, observation indicators
小鼠跳台装置为六个长方形反射箱，大小为32cm*22.5cm*33cm，用黑色塑料板分隔成为6间，底面为不锈钢网栅，网栅间距为0.5cm，每间左后角放置一高和直径4.5cm的橡胶站台，将小鼠面向墙角轻轻放置与站台上，适应环境3min，然后通以36V电流，若动物跳下站台则受电击，其正常反应应该是跳回站台以躲避伤害性刺激，多数动物可能会再次或多次跳至网栅上逃避电击，跳下时以小鼠双足同时接触铜栅为触电，视为错误次数，训练5min，24h后进行测试，此即记忆保持测验，记录5min内第一次跳下平台的潜伏期和错误次数。The mouse jumping platform device consists of six rectangular reflection boxes with a size of 32cm*22.5cm*33cm. They are divided into 6 rooms with black plastic plates. The bottom surface is a stainless steel grid with a grid spacing of 0.5cm. And a rubber platform with a diameter of 4.5cm, place the mouse on the platform gently facing the corner, adapt to the environment for 3 minutes, and then pass a 36V current. If the animal jumps off the platform, it will be shocked. Its normal reaction should be to jump back to the platform to avoid injury Sexual stimulation, most animals may jump to the grid again or several times to escape the electric shock. When jumping, the mouse’s feet touch the copper grid at the same time as the electric shock, which is regarded as the number of errors. After training for 5 minutes, test it after 24 hours, which is memory. Keep the test, record the latency and the number of mistakes when jumping off the platform for the first time within 5 minutes.
新接收动物标号，检疫5d，检疫完成后动物按体重随机分为6组，如前所述。按体重灌胃给药，每日一次，连续10d，空白组及模型组给予蒸馏水，末次给药后1h开始进行跳台训练，训练前20min除空白组外各组腹腔注射氢溴酸东莨菪碱3mg/kg，空白组给予相应体积生理盐水，训练5min，24h后测试记忆成绩，观察并记录5min内第一次跳下平台的潜伏期和错误次数，5min内未跳下的小鼠其跳台潜伏期按300s计算。Newly received animals were labeled and quarantined for 5 days. After the quarantine was completed, the animals were randomly divided into 6 groups according to body weight, as described above. Gavage administration according to body weight, once a day, for 10 consecutive days, distilled water was given to the blank group and model group, platform training was started 1 hour after the last administration, and 3 mg/kg of scopolamine hydrobromide was injected intraperitoneally into each group except the blank group 20 minutes before training , the blank group was given the corresponding volume of normal saline, trained for 5 minutes, and tested the memory score after 24 hours. Observe and record the latency and the number of mistakes when jumping off the platform for the first time within 5 minutes.
2.7相关工作人员通知2.7 Relevant staff notification
购买动物时通知动物室，在动物出现异常情况时通知病理室进行处理。Notify the animal room when purchasing animals, and notify the pathology room for processing when animals appear abnormal.
2.8仪器系统2.8 Instrument system
DT2000电子天平，常熟双杰测试仪器厂。DT2000 electronic balance, Changshu Shuangjie Test Instrument Factory.
SL-2001N电子天平，上海民桥精密科学仪器有限公司。SL-2001N electronic balance, Shanghai Minqiao Precision Scientific Instrument Co., Ltd.
秒表，深圳市惠波工贸有限公司。Stopwatch, Shenzhen Huibo Industry and Trade Co., Ltd.
DT200小鼠跳台仪，成都泰盟科技有限公司。DT200 mouse jumping platform, Chengdu Taimeng Technology Co., Ltd.
2.9统计方法2.9 Statistical methods
实验数据采用SPSS11.5统计软件进行分析处理，统计结果用均数±标准差
表示，首先进行正态性检验，符合正态分布的数据，均数比较用单因素方差分析(One-WayANOVA)，若方差齐，两两比较采用最小显著差法(LSD)，若方差不齐则采用Dunnett’s T3检验行两两比较；如不符合正态分布，则用非参数检验进行统计分析。
The experimental data is analyzed and processed by SPSS11.5 statistical software, and the statistical results are expressed as mean ± standard deviation It means that firstly, the normality test is carried out, and the data conforming to the normal distribution are compared with one-way analysis of variance (One-WayANOVA). If the variances are equal, the least significant difference method (LSD) is used for pairwise comparison. The Dunnett's T3 test was used for pairwise comparison; if the normal distribution was not met, the non-parametric test was used for statistical analysis.
3结果3 results
由表10可见，与空白组比较，模型组潜伏期明显缩短(P<0.05)，错误次数明显增加(P<0.05)，此二指标显示东莨菪碱造模成功；与模型组比较，对照药组潜伏期与错误次数无显著差异(P>0.05)，RJYZ2组错误次数明显减少(P<0.05)，RJYZ1组潜伏期明显延长(P<0.05)，错误次数明显减少(P<0.05)。As can be seen from Table 10, compared with the blank group, the incubation period of the model group was significantly shortened (P<0.05), and the number of errors was significantly increased (P<0.05). These two indicators showed that scopolamine was successfully modeled; There was no significant difference in the number of mistakes (P>0.05), but the number of mistakes in the RJYZ2 group was significantly reduced (P<0.05), and the latency of the RJYZ1 group was significantly prolonged (P<0.05), and the number of mistakes was significantly reduced (P<0.05).
表10 RJYZ对东莨菪碱致小鼠记忆获得障碍模型的影响实验跳台结果
Table 10 The effect of RJYZ on the model of scopolamine-induced memory acquisition impairment in mice
注：与空白组比较：
△P＜0.05，
△△P＜0.01；与模型组比较：*P＜0.05，**P＜0.01。
Note: Compared with the blank group: △ P<0.05, △△ P<0.01; compared with the model group: *P<0.05, **P<0.01.
4结论4 Conclusion
本实验结果说明了本发明药物组合物对东莨菪碱致小鼠记忆获得障碍有一定的改善作用。The results of this experiment illustrate that the pharmaceutical composition of the present invention has a certain improvement effect on the impairment of memory acquisition in mice induced by scopolamine.
5讨论5 discussions
学习记忆障碍是老年痴呆的一种重要表现，是人类和动物赖以生存所不可缺少的重要脑功能之一，学习是神经系统接受外界环境变化获得新行为和经验的过程，记忆是学习后经验的保持和再现。一般把学习记忆分为3个阶段，即获得、巩固和再现，东莨菪碱为M胆碱受体阻断剂，可对抗乙酰胆碱，能模拟乙酰胆碱分泌不足造成可逆的记忆障碍，是常用的抗老年性痴呆药物研究的初筛模型。Impairment of learning and memory is an important manifestation of senile dementia, and it is one of the important brain functions that are indispensable for the survival of humans and animals. Learning is the process by which the nervous system accepts changes in the external environment to acquire new behaviors and experiences. Memory is the experience after learning. maintenance and reproduction. Generally, learning and memory are divided into three stages, namely acquisition, consolidation and reproduction. Scopolamine is an M choline receptor blocker, which can resist acetylcholine and can simulate reversible memory impairment caused by insufficient secretion of acetylcholine. It is a commonly used anti-senile dementia Primary screening models for drug research.
跳台实验是常用的测试学习记忆的行为学方法，但其准确度易受诸多因素的影响，如实 验环境、实验动物、非特异性干扰、奖励和惩罚效应等，Platform jumping test is a commonly used behavioral method for testing learning and memory, but its accuracy is easily affected by many factors, such as experimental environment, experimental animals, non-specific interference, reward and punishment effects, etc.
本次实验中借鉴了本实验室前期积累的经验，实验中对动物进食量加以控制，使体重不至于偏大，减少因体重过大致上台困难的影响，以及保持安静的实验环境，室内温湿度、光照适宜并保持一致等。RJYZ对东莨菪碱致小鼠记忆获得障碍有一定的改善作用。In this experiment, the experience accumulated in the previous laboratory was used for reference. In the experiment, the food intake of the animals was controlled so that the body weight would not be too large, and the influence of difficulty in getting on stage due to overweight was reduced, and the experimental environment was kept quiet, and the indoor temperature and humidity , Lighting is appropriate and consistent. RJYZ has a certain improvement effect on the impairment of memory acquisition in mice induced by scopolamine.
试验总结论General conclusion of the test
Aβ
42寡聚体致AD大鼠学习记忆障碍模型实验显示，RJYZ两个组别均不同程度的减少水迷宫潜伏期及总路程，增加站台穿越次数及站台所在象限时间，减少胆碱系统海马ACHE活力及脂质过氧化产物MDA含量，减少Aβ、p-Tau及相关凋亡、炎症因子表达。另外采用ICR小鼠乙醇致记忆再现缺失、亚硝酸钠致记忆巩固障碍、东莨菪碱致记忆获得障碍三种记忆缺失的动物模型，跳台实验结果均显示RJYZ可延长潜伏期及减少错误次数。
Aβ 42 oligomer-induced learning and memory impairment model experiments in AD rats showed that both groups of RJYZ reduced the water maze latency and total distance to varying degrees, increased the number of platform crossings and the quadrant time of the platform, and reduced the ACHE activity of the hippocampus in the choline system and the content of lipid peroxidation product MDA, and reduce the expression of Aβ, p-Tau and related apoptosis and inflammatory factors. In addition, using three animal models of memory loss in ICR mice, ethanol-induced memory loss, sodium nitrite-induced memory consolidation impairment, and scopolamine-induced memory acquisition impairment, the platform jumping test results showed that RJYZ can prolong the latency and reduce the number of errors.
综合以上结果，RJYZ对Aβ
42寡聚体致AD大鼠学习记忆能力有明显改善作用，其作用可能与改善胆碱能系统功能、减轻氧化应激损伤、减少神经细胞凋亡、抑制炎症反应有关。同时采用记忆再现缺失、记忆巩固障碍、记忆获得障碍三种记忆缺失的动物模型，RJYZ均有明显的改善学习记忆的作用。
Based on the above results, RJYZ can significantly improve the learning and memory ability of Aβ42 oligomer-induced AD rats, which may be related to improving the function of cholinergic system, reducing oxidative stress damage, reducing nerve cell apoptosis, and inhibiting inflammatory response . At the same time, RJYZ can obviously improve learning and memory in animal models of memory loss, memory consolidation disorder and memory acquisition disorder.
对照药组与RJYZ组比较，实验结果中无显著差异，未体现出好的效果。Compared with the control drug group and the RJYZ group, there was no significant difference in the experimental results, which did not show a good effect.
实施例1：Example 1:
管花肉苁蓉400g，刺五加800g，益智仁400g，当归400g。Cistanche 400g, Acanthopanax 800g, Yizhiren 400g, Angelica 400g.
1、取益智仁，破碎，密闭，备用；1. Take Yizhiren, break it, seal it, and reserve it;
2、取管花肉苁蓉、刺五加，用50％乙醇回流提取三次，每次2小时，每次加50％乙醇10倍量，提取液滤过，滤液减压浓缩至相对密度为1.05～1.10(60℃)的清膏，备用；2. Take Cistanche cistanche and Acanthopanax, extract three times with 50% ethanol under reflux, each time for 2 hours, add 10 times the amount of 50% ethanol each time, filter the extract, and concentrate the filtrate under reduced pressure to a relative density of 1.05-1.10 (60°C) clear ointment, set aside;
3、取益智仁、当归，加10倍量的水，加热蒸馏8小时，收集挥发油；药渣加水煎煮二次，每次1.5小时，每次加水10倍量，两次煎液与蒸馏后的水煎液合并，减压浓缩至相对密度为1.05～1.10(60℃)的清膏，与上述清膏合并，继续减压浓缩至相对密度为1.20-1.30(60℃)的稠浸膏；3. Take Yizhi Ren and Angelica, add 10 times the amount of water, heat and distill for 8 hours, and collect the volatile oil; add water to the dregs and decoct twice, each time for 1.5 hours, add 10 times the amount of water each time, decoct twice and distill The final decoctions are combined, concentrated under reduced pressure to a clear extract with a relative density of 1.05-1.10 (60°C), combined with the above clear extract, and then concentrated under reduced pressure to a thick extract with a relative density of 1.20-1.30 (60°C) ;
4、取以上稠浸膏在温度110±5℃条件下真空干燥，粉碎，即得干膏粉。4. Take the above thick extract, dry it in vacuum at a temperature of 110±5°C, and pulverize it to obtain dry paste powder.
干膏粉和挥发油共同构成了本发明药物组合物的活性组分。Dry cream powder and volatile oil together constitute the active components of the pharmaceutical composition of the present invention.
实施例2：Example 2:
肉苁蓉380份，刺五加700份，益智仁400份，当归500份。Cistanche 380 parts, Acanthopanax 700 parts, Yizhiren 400 parts, Angelica 500 parts.
(1)原料处理：取益智仁破碎；(1) Raw material processing: take Yizhi kernels and crush them;
(2)称量：按配方比例称取肉苁蓉，刺五加、益智仁、当归备用；(2) Weighing: take Cistanche deserticola, Acanthopanax senticosus, Yizhiren, Angelica sinensis for subsequent use according to the proportion of the formula;
(3)取肉苁蓉、刺五加，用60％乙醇回流提取3次，每次2小时，每次加10倍量，提取液滤过，滤液减压浓缩至相对密度为1.05～1.10(60℃)的清膏，备用；(3) Take Cistanche deserticola and Acanthopanax, extract 3 times with 60% ethanol under reflux, each time for 2 hours, add 10 times the amount each time, filter the extract, and concentrate the filtrate under reduced pressure to a relative density of 1.05 to 1.10 (60°C ) clear ointment, set aside;
(4)取益智仁、当归，加10倍量的水，加热蒸馏8小时，收集挥发油；水煎液备用；药渣加10倍量的水，煎煮二次，每次1.5小时，两次煎液与蒸馏后的水煎液合并，减压浓缩至相对密度为1.05～1.10的清膏，与步骤(3)所得清膏合并，继续减压浓缩至相对密度为1.20-1.30的稠浸膏；干燥，粉碎，得干膏粉；(4) Take Yizhi Ren and Angelica, add 10 times the amount of water, heat and distill for 8 hours, and collect the volatile oil; The sub-decoction is combined with the distilled water decoction, concentrated under reduced pressure to a clear paste with a relative density of 1.05-1.10, combined with the clear paste obtained in step (3), and continued to be concentrated under reduced pressure to a thick immersion with a relative density of 1.20-1.30 Ointment; dried, crushed to obtain dry ointment powder;
(5)挥发油进行包合后，干燥，粉碎成细粉；(5) After the volatile oil is clathrated, it is dried and pulverized into fine powder;
(6)将步骤(4)的干膏粉与步骤(5)的细粉混合，加入辅料，制备成片剂即得。(6) Mix the dry cream powder in step (4) with the fine powder in step (5), add auxiliary materials, and prepare it into tablets.
实施例3：Example 3:
肉苁蓉600g，刺五加400g，益智仁500g，当归500g。Cistanche 600g, Acanthopanax 400g, Yizhiren 500g, Angelica 500g.
(1)原料处理：取益智仁破碎；(1) Raw material processing: take Yizhi kernels and crush them;
(2)称量：按配方比例称取肉苁蓉，刺五加、益智仁、当归备用；(2) Weighing: take Cistanche deserticola, Acanthopanax senticosus, Yizhiren, Angelica sinensis for subsequent use according to the proportion of the formula;
(3)取肉苁蓉、刺五加，用70％乙醇回流提取2次，每次3小时，每次加8倍量，提取液滤过，滤液减压浓缩至相对密度为1.05～1.10(60℃)的清膏，备用；(3) Take Cistanche deserticola and Acanthopanax, extract twice with 70% ethanol under reflux, each time for 3 hours, add 8 times the amount each time, filter the extract, and concentrate the filtrate under reduced pressure to a relative density of 1.05 to 1.10 (60°C ) clear ointment, set aside;
(4)取益智仁、当归，加12倍量的水，加热蒸馏10小时，收集挥发油；水煎液备用；药渣加12倍量的水，煎煮二次，每次1.5小时，两次煎液与蒸馏后的水煎液合并，减压浓缩至相对密度为1.05～1.10的清膏，与步骤(3)所得清膏合并，继续减压浓缩至相对密度为1.20-1.30的稠浸膏；干燥，粉碎，得干膏粉；(4) Take Yizhi Ren and Angelica, add 12 times the amount of water, heat and distill for 10 hours, and collect the volatile oil; The sub-decoction is combined with the distilled water decoction, concentrated under reduced pressure to a clear paste with a relative density of 1.05-1.10, combined with the clear paste obtained in step (3), and continued to be concentrated under reduced pressure to a thick immersion with a relative density of 1.20-1.30 Ointment; dried, crushed to obtain dry ointment powder;
(5)挥发油进行包合后，干燥，粉碎成细粉；(5) After the volatile oil is clathrated, it is dried and pulverized into fine powder;
(6)将步骤(4)的干膏粉与步骤(5)的细粉混合，加入适当辅料，制备成胶囊剂即得。(6) Mix the dry paste powder in step (4) with the fine powder in step (5), add appropriate auxiliary materials, and prepare capsules.
实施例4：Example 4:
肉苁蓉500g，刺五加600份，益智仁500份，当归500份。Cistanche 500g, Acanthopanax 600 parts, Yizhiren 500 parts, Angelica 500 parts.
(1)原料处理：取益智仁破碎；(1) Raw material processing: take Yizhi kernels and crush them;
(2)称量：按配方比例称取肉苁蓉，刺五加、益智仁、当归备用；(2) Weighing: take Cistanche deserticola, Acanthopanax senticosus, Yizhiren, Angelica sinensis for subsequent use according to the proportion of the formula;
(3)取肉苁蓉、刺五加，用80％乙醇回流提取2次，每次1小时，每次加10倍量，提取液滤过，滤液减压浓缩至相对密度为1.05～1.10(60℃)的清膏，备用；(3) Take Cistanche deserticola and Acanthopanax, extract twice with 80% ethanol under reflux, each time for 1 hour, add 10 times the amount each time, filter the extract, and concentrate the filtrate under reduced pressure to a relative density of 1.05 to 1.10 (60°C ) clear ointment, set aside;
(4)取益智仁、当归，加8倍量的水，加热蒸馏9小时，收集挥发油；水煎液备用；药渣加8倍量的水，煎煮二次，每次1.5小时，两次煎液与蒸馏后的水煎液合并，减压浓缩至相对密度为1.05～1.10的清膏，与步骤(3)所得清膏合并，继续减压浓缩至相对密度为1.20-1.30 的稠浸膏；干燥，粉碎，得干膏粉；(4) Take Yizhi Ren and Angelica, add 8 times the amount of water, heat and distill for 9 hours, and collect the volatile oil; Combine the sub-decoction with the distilled water decoction, concentrate under reduced pressure to a clear paste with a relative density of 1.05-1.10, combine it with the clear paste obtained in step (3), and continue to concentrate under reduced pressure to a thick immersion with a relative density of 1.20-1.30 Ointment; dried, crushed to obtain dry ointment powder;
(5)挥发油进行包合后，干燥，粉碎成细粉；(5) After the volatile oil is clathrated, it is dried and pulverized into fine powder;
(6)将步骤(4)的干膏粉与步骤(5)的细粉混合，加入辅料，制备成丸剂即得。(6) Mix the dry cream powder in step (4) with the fine powder in step (5), add auxiliary materials, and prepare into pills.
对照药组：Control drug group:
刺五加800g；人参267g；益智仁267g；五味子178gAcanthopanax 800g; Ginseng 267g; Yizhiren 267g; Schisandra 178g
(1)原料处理：取刺五加、益智仁、五味子饮片，洗净备用；人参粉碎，过80目筛，
60Co辐照灭菌，辐照剂量3kGy，备用；
(1) Raw material processing: take Acanthopanax, Yizhiren, and Schisandra chinensis decoction pieces, wash and set aside; Ginseng is pulverized, passed through a 80-mesh sieve, sterilized by 60 Co irradiation, and the irradiation dose is 3kGy, set aside;
(2)称量：按配方比例称取刺五加、益智仁、五味子及人参粉，备用；(2) Weighing: take Acanthopanax, Yizhiren, Schisandra chinensis and ginseng powder according to the formula ratio, and set aside;
(3)提取：将称量好的刺五加、益智仁、五味子，加水提取3次，每次1小时，第一次加9倍水，第二、三次分别加8倍水，提取液滤过，合并，备用；(3) Extraction: Add water to extract the weighed Acanthopanax, Yizhiren, and Schisandra chinensis 3 times, each time for 1 hour, add 9 times of water for the first time, add 8 times of water for the second and third times, and extract filter, merge, reserve;
(4)浓缩：提取液减压浓缩，浓缩至至60℃热测相对密度1.05～1.10的清膏；(4) Concentration: the extract is concentrated under reduced pressure, and concentrated to a clear paste with a relative density of 1.05 to 1.10 at 60°C;
(5)真空干燥：采用真空烘箱干燥，收集干膏，备用；(5) Vacuum drying: adopt vacuum oven to dry, collect dry paste, for subsequent use;
(6)干膏粉碎：将干膏粉碎，收集细粉，备用；(6) Dry paste crushing: dry paste is crushed, fine powder is collected, and set aside;
(7)将干膏粉、人参灭菌粉混合均匀，干法制粒，整粒、总混后，填充胶囊即得。(7) Mix dry paste powder and sterilized ginseng powder evenly, dry granulate, granulate and mix, and fill capsules to obtain.
Claims (11)
- 一种制备治疗老年痴呆的药物组合物，其特征在于该组合物由如下重量份的原料药制成：A pharmaceutical composition for the treatment of senile dementia, characterized in that the composition is made of the following raw materials by weight:肉苁蓉200-600份，刺五加400-1200份，益智仁200-600份，当归200-600份。Cistanche 200-600 parts, Acanthopanax 400-1200 parts, Yizhiren 200-600 parts, Angelica 200-600 parts.
- 如权利要求1所述的组合物，其特征在于该组合物由如下重量份的原料药制成：The composition according to claim 1, characterized in that the composition is made of the following bulk drug in parts by weight:肉苁蓉300-500份，刺五加600-1000份，益智仁300-500份，当归300-500份。Cistanche 300-500 parts, Acanthopanax 600-1000 parts, Yizhiren 300-500 parts, Angelica 300-500 parts.
- 如权利要求1所述的组合物，其特征在于该组合物由如下重量份的原料药制成：The composition according to claim 1, characterized in that the composition is made of the following bulk drug in parts by weight:肉苁蓉400份，刺五加800份，益智仁400份，当归400份。Cistanche 400 parts, Acanthopanax 800 parts, Yizhiren 400 parts, Angelica 400 parts.
- 如权利要求1所述的组合物，其特征在于该组合物由如下重量份的原料药制成：The composition according to claim 1, characterized in that the composition is made of the following bulk drug in parts by weight:肉苁蓉380份，刺五加700份，益智仁400份，当归500份。Cistanche 380 parts, Acanthopanax 700 parts, Yizhiren 400 parts, Angelica 500 parts.
- 如权利要求1所述的组合物，其特征在于该组合物由如下重量份的原料药制成：The composition according to claim 1, characterized in that the composition is made of the following bulk drug in parts by weight:肉苁蓉600份，刺五加400份，益智仁500份，当归500份。Cistanche 600 parts, Acanthopanax 400 parts, Yizhiren 500 parts, Angelica 500 parts.
- 如权利要求1-5中任一项所述的组合物，其特征在于其活性组分制备包括以下步骤：The composition according to any one of claims 1-5, characterized in that the preparation of its active ingredient comprises the following steps:(1)原料处理：取益智仁破碎；(1) Raw material processing: take Yizhi kernels and crush them;(2)称量：按配方比例称取肉苁蓉，刺五加、益智仁、当归备用；(2) Weighing: take Cistanche deserticola, Acanthopanax senticosus, Yizhiren, Angelica sinensis for subsequent use according to the proportion of the formula;(3)取肉苁蓉、刺五加，用50％-80％乙醇回流提取2-3次，每次1-3小时，每次加8-10倍量，提取液滤过，滤液减压浓缩至相对密度为1.05～1.10(60℃)的清膏，备用；(3) Get Cistanche deserticola and Acanthopanax, reflux extraction with 50%-80% ethanol for 2-3 times, each time for 1-3 hours, add 8-10 times the amount each time, filter the extract, and concentrate the filtrate under reduced pressure to Clear paste with a relative density of 1.05-1.10 (60°C), set aside;(4)取益智仁、当归，加8-12倍量的水，加热蒸馏6-10小时，收集挥发油；水煎液备用；药渣加8-12倍量的水，煎煮二次，每次1.5小时，两次煎液与蒸馏后的水煎液合并，减压浓缩至相对密度为1.05～1.10的清膏，与步骤(3)所得清膏合并，继续减压浓缩至相对密度为1.20-1.30的稠浸膏；(4) Take Yizhi Ren and Angelica, add 8-12 times the amount of water, heat and distill for 6-10 hours, and collect the volatile oil; decoct the liquid for later use; add 8-12 times the amount of water to the dregs, decoct twice, Each time for 1.5 hours, the two decoctions were combined with the distilled water decoction, concentrated under reduced pressure to a clear paste with a relative density of 1.05 to 1.10, combined with the clear paste obtained in step (3), and continued to be concentrated under reduced pressure until the relative density was 1.20-1.30 thick extract;(5)取步骤(4)所得稠浸膏干燥，粉碎，所得干膏粉与挥发油共同构成本发明药物组合物的活性组分。(5) The thick extract obtained in step (4) is dried, pulverized, and the obtained dry extract powder and volatile oil together constitute the active component of the pharmaceutical composition of the present invention.
- 如权利要求1-5中任一项所述的组合物，其特征在于肉苁蓉为管花肉苁蓉。The composition according to any one of claims 1-5, characterized in that Herba Cistanche is Herba Cistanche.
- 如权利要求1-5中任一项所述的组合物，其特征在于该组合物可制备成的制剂剂型为胶囊剂、片剂、丸剂、散剂或膏剂。The composition according to any one of claims 1-5, characterized in that the composition can be prepared in the form of capsules, tablets, pills, powders or ointments.
- 如权利要求8所述的组合物，其特征在于所述片剂制备方法为：composition as claimed in claim 8, is characterized in that described tablet preparation method is:(1)原料处理：取益智仁破碎；(1) Raw material processing: take Yizhi kernels and crush them;(2)称量：按配方比例称取肉苁蓉，刺五加、益智仁、当归备用；(2) Weighing: take Cistanche deserticola, Acanthopanax senticosus, Yizhiren, Angelica sinensis for subsequent use according to the proportion of the formula;(3)取肉苁蓉、刺五加，用50％-80％乙醇回流提取2-3次，每次1-3小时，每次加8-10倍量，提取液滤过，滤液减压浓缩至相对密度为1.05～1.10(60℃)的清膏，备用；(3) Get Cistanche deserticola and Acanthopanax, reflux extraction with 50%-80% ethanol for 2-3 times, each time for 1-3 hours, add 8-10 times the amount each time, filter the extract, and concentrate the filtrate under reduced pressure to Clear paste with a relative density of 1.05-1.10 (60°C), set aside;(4)取益智仁、当归，加8-12倍量的水，加热蒸馏6-10小时，收集挥发油；水煎液备用； 药渣加8-12倍量的水，煎煮二次，每次1.5小时，两次煎液与蒸馏后的水煎液合并，减压浓缩至相对密度为1.05～1.10的清膏，与步骤(3)所得清膏合并，继续减压浓缩至相对密度为1.20-1.30的稠浸膏；干燥，粉碎，得干膏粉；(4) Take Yizhi Ren and Angelica, add 8-12 times the amount of water, heat and distill for 6-10 hours, collect volatile oil; decoct in water for later use; add 8-12 times the amount of water to the dregs, decoct twice, Each time for 1.5 hours, the two decoctions were combined with the distilled water decoction, concentrated under reduced pressure to a clear paste with a relative density of 1.05 to 1.10, combined with the clear paste obtained in step (3), and continued to be concentrated under reduced pressure until the relative density was 1.20-1.30 thick extract; dried and crushed to obtain dry paste powder;(5)挥发油进行包合后，干燥，粉碎成细粉；(5) After the volatile oil is clathrated, it is dried and pulverized into fine powder;(6)将步骤(4)的干膏粉与步骤(5)的细粉混合，加入辅料，制备成片剂即得。(6) Mix the dry cream powder in step (4) with the fine powder in step (5), add auxiliary materials, and prepare it into tablets.
- 如权利要求1-5任一所述的组合物，其特征在于该组合物在改善记忆障碍药物中的应用。The composition according to any one of claims 1-5, characterized in that the composition is used in medicines for improving memory impairment.
- 如权利要求1-5任一所述的组合物，其特征在于该组合物在改善胆碱能系统功能、减轻氧化应激损伤、减少神经细胞凋亡或抑制炎症反应药物中的应用。The composition according to any one of claims 1-5, characterized in that the composition is used as a drug for improving cholinergic system function, reducing oxidative stress damage, reducing nerve cell apoptosis or inhibiting inflammatory response.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110724744.8 | 2021-06-29 | ||
| CN202110724744.8A CN115531500A (en) | 2021-06-29 | 2021-06-29 | Composition for treating senile dementia and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2023273626A1 true WO2023273626A1 (en) | 2023-01-05 |
Family
ID=84692469
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/CN2022/092323 WO2023273626A1 (en) | 2021-06-29 | 2022-05-11 | Composition for treating alzheimer's disease and preparation method therefor |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN115531500A (en) |
| WO (1) | WO2023273626A1 (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102698172A (en) * | 2012-05-16 | 2012-10-03 | 江苏苏南药业实业有限公司 | Pharmaceutical composition for treating senile dementia |
| CN107320674A (en) * | 2017-06-23 | 2017-11-07 | 北京中医药大学东方医院 | A kind of Chinese medicine composition and its application |
| CN108210818A (en) * | 2018-04-16 | 2018-06-29 | 成都中医药大学 | A kind of pharmaceutical composition for preventing neurodegenerative disease and its preparation method and application |
-
2021
- 2021-06-29 CN CN202110724744.8A patent/CN115531500A/en active Pending
-
2022
- 2022-05-11 WO PCT/CN2022/092323 patent/WO2023273626A1/en unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102698172A (en) * | 2012-05-16 | 2012-10-03 | 江苏苏南药业实业有限公司 | Pharmaceutical composition for treating senile dementia |
| CN107320674A (en) * | 2017-06-23 | 2017-11-07 | 北京中医药大学东方医院 | A kind of Chinese medicine composition and its application |
| CN108210818A (en) * | 2018-04-16 | 2018-06-29 | 成都中医药大学 | A kind of pharmaceutical composition for preventing neurodegenerative disease and its preparation method and application |
Non-Patent Citations (2)
| Title |
|---|
| LI XUENA, LI XIANG-JUN; WANG HONG-TAO; WEI GANG; LIU XUE-TAO; CHANG LI-PING: "Effects of Yizhi Capsule on Learning and Memory in Rat AD Model", CHINESE JOURNAL OF EXPERIMENTAL TRADITIONAL MEDICAL FORMULAE, ZHONGGUO ZHONGYI KEXUEYUAN ZHONGYAO YANJIUSUO, CN, vol. 21, no. 5, 5 March 2015 (2015-03-05), CN , pages 115 - 119, XP093019293, ISSN: 1005-9903, DOI: 10.13422/j.cnki.syfjx.2015050115 * |
| ZHAN YAN, MA DI-HUI, ZHANG YU: "Effects of Yizhikoufuye on Apoptosis in Different Cerebral Regions of Rats with Alzheimer's Disease", JOURNAL OF JILIN UNIVERSITY MEDICINE EDITION - JILIN DAXUE XUEBAO (YIXUE BAN), JILIN DAXUE, CN, vol. 33, no. 1, 20 March 2006 (2006-03-20), CN , pages 123 - 126, XP093019289, ISSN: 1671-587X, DOI: 10.13481/j.1671-587x.2007.01.046 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115531500A (en) | 2022-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0715070B1 (en) | USE OF ESCIN IN THE PRODUCTION OF PHARMACEUTICAL PREPARATIONS FOR TREATING MEDIATED OR CAUSED DISEASES CAUSED BY ACTIVATED GRANULOCYTES | |
| US9655870B2 (en) | Homeopathic drug composition and methods of use thereof | |
| CN103405742B (en) | Drug composition for treating infantile diarrhea and preparation method thereof | |
| US20230125425A1 (en) | Traditional chinese medicine extract composition with function of regulating depressive emotion and preparation method and traditional chinese medicine preparation thereof | |
| WO2023273626A1 (en) | Composition for treating alzheimer's disease and preparation method therefor | |
| JP2007131592A (en) | Prophylactic and/or therapeutic composition for pollinosis and/or house dust allergy comprising propolis | |
| CN103735761A (en) | Pharmaceutical composition for preventing and treating alzheimer disease and preparation method of pharmaceutical composition | |
| CN101066294B (en) | Chinese medicine prepn for invigorating kidney to reduce urination and its prepn | |
| KR101509056B1 (en) | Composition having brain function and congnition enhancing activity comprising ginseng mixed herbal extracts, ginsenoside Rg2 and ginsenoside F2 | |
| CN102225155B (en) | Medicament composition for treating pulmonary fibrosis | |
| CN107648482A (en) | A kind of Chinese medicine composition for being used to treat nerve degenerative diseases | |
| CN111053819A (en) | Traditional Chinese medicine composition extract and application thereof in preparation of protein expression regulator | |
| TWI788228B (en) | Use of mangosteen fruit shell extract in the preparation of a medicament for treating bedsores | |
| Yeh et al. | Therapeutic Effect of Yi-Chi-Tsung-Ming-Tang on Amyloid β 1− 40-Induced Alzheimer's Disease-Like Phenotype via an Increase of Acetylcholine and Decrease of Amyloid β | |
| CN116688058B (en) | Li medicine for impotence, preparation method and application thereof | |
| CN116726083B (en) | Traditional Chinese medicine composition for treating chronic prostatitis | |
| CN115837029B (en) | Application of codonopsis pilosula acetylenic glycoside in preparation of medicines for treating allergic rhinitis | |
| US20010043959A1 (en) | Composition and method for treating the effects of diseases and maladies | |
| Orinbasarovna et al. | MODERN PHARMACOTHERAPY OF TREATMENT OF LIVER DISEASES | |
| Varsakiya et al. | Role of Ayurveda in the Management of Ekkushtha (Palmar Psoriasis)-A Case Report | |
| CN107865953B (en) | Traditional Chinese medicine compound preparation for treating salivation and nocturia increase as well as preparation method and application thereof | |
| Korade et al. | Management of Jirna Kasa (Chronic cough) in children with ayurvedic regimen a single case study | |
| Dilawar et al. | MANAGEMENT OF SHVITRA (VITILIGO) BY AN AYURVEDIC REGIME-A CASE STUDY | |
| Ajmalhussain | Assessment of the Neuro-Protective Effects of Combination of Acorus Calamus and Eugenol in Alzheimer’s Animal Model | |
| TW202310829A (en) | Preventive or improver for nocturia, halfway awakening or frequent urination |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22831453 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |